[
  {
    "id": "path_9947a8e3a756",
    "question": "For a patient with stage IIIA non-small cell lung cancer (T1–2, N2) and an R1 resection margin after surgery, if consolidation chemoradiation is considered, does this implicitly require the absence of distant metastases at the time of initiation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
            "R1; Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, consolidation chemoradiation after an R1 resection in stage IIIA non-small cell lung cancer is indicated only in the absence of distant metastases, as its intent is local-regional control; the presence of distant metastases would shift management toward systemic or palliative therapies.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b3887baaeadc",
    "question": "In a patient with non-small cell lung cancer who presents with separate pulmonary nodules located in the contralateral lung (M1a), and is otherwise a candidate for surgery, does the outlined approach of surgery after preoperative systemic therapy still apply, or does this site of disease represent a boundary beyond which surgical resection is not indicated?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
            "Surgery after preoperative systemic therapy, if planned",
            "N0–1",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "For non-small cell lung cancer with separate pulmonary nodules in the contralateral lung (M1a), this finding classifies the disease as metastatic. Surgical resection is generally not indicated for M1a disease, and the described strategy of surgery after preoperative systemic therapy applies only to cases with nodules in the same or ipsilateral lung, not in the contralateral lung.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_30ca67aea27e",
    "question": "In a patient with metastatic (stage IV, M1) invasive breast cancer that is ER- and/or PR-positive and HER2-negative, who presents with rapid progression of liver metastases resulting in impaired hepatic function and clinical symptoms, should initial systemic therapy be prioritized over endocrine therapy, regardless of previous endocrine sensitivity?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Metastatic (M1) invasive breast cancer",
            "Stage IV (M1) or Recurrent disease",
            "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
            "Stage IV (M1) or Recurrent",
            "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
            "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
            "Recurrent unresectable (local or regional) or stage IV (M1) disease",
            "Bone disease not present",
            "ER- and/or PR-positive; HER2-negative",
            "BINV-22",
            "Visceral crisis",
            "Consider initial systemic therapy",
            "Continue therapy until progression or unacceptable toxicity",
            "Progression",
            "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
            "Alternate systemic therapy",
            "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
            "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
          ]
        }
      }
    ],
    "answer": "Yes. In the setting of visceral crisis—characterized by life-threatening organ dysfunction such as rapidly progressive liver metastases—initial systemic cytotoxic therapy is prioritized over endocrine therapy, irrespective of hormone receptor sensitivity or prior endocrine responsiveness, to rapidly control disease and stabilize organ function.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_4ca33f42da3a",
    "question": "In a newly diagnosed patient with stage IVA non-small cell lung cancer (adenocarcinoma subtype) whose tumor harbors an EGFR exon 19 deletion, if molecular testing for ALK rearrangement is still pending, is it appropriate to initiate first-line EGFR-targeted therapy before ALK results are available?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "EGFR exon 19 deletion or exon 21 L858R mutation positive",
            "EGFR exon 19 deletion or exon 21 L858R mutations",
            "EGFR mutation discovered prior to first-line systemic therapy",
            "Useful in Certain Circumstances: Erlotinib + ramucirumab or Erlotinib + bevacizumab or Dacomitinib (category 1) or Afatinib (category 1) or Erlotinib (category 1) or Gefitinib (category 1)",
            "Progression: Subsequent Therapy (NSCL-23)"
          ]
        }
      }
    ],
    "answer": "Yes, it is appropriate to start first-line EGFR-targeted therapy in a patient with stage IVA non-small cell lung adenocarcinoma harboring an EGFR exon 19 deletion, even if ALK testing is pending. This is because actionable EGFR mutations independently justify targeted therapy initiation regardless of ALK status, given their rarity of overlap and immediate treatment priority.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_aa294a369042",
    "question": "In a patient with stage IIIC (T3, N3) non-small cell lung cancer who develops a resectable isolated locoregional recurrence after initial definitive therapy and has no evidence of disseminated disease, is surgical resection preferred over external-beam radiation therapy or stereotactic ablative body radiotherapy (SABR)?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, for a patient with stage IIIC (T3, N3) non-small cell lung cancer and a resectable isolated locoregional recurrence without evidence of disseminated disease, surgical resection is the preferred treatment option compared to external-beam radiation therapy or SABR. Resection should be prioritized when the recurrence is deemed technically operable and the patient is fit for surgery.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_22f18a8a0527",
    "question": "In patients with stage I–II non–small cell lung cancer who underwent primary treatment with surgery and have no clinical or radiographic evidence of disease, is routine brain MRI with contrast required during scheduled surveillance imaging?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "No, routine brain MRI with contrast is not indicated for surveillance in stage I–II non–small cell lung cancer patients treated with surgery and without clinical or radiographic evidence of disease; surveillance should use history, physical exam, and periodic chest CT, reserving brain MRI for cases of suspected recurrence or neurologic symptoms.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e57b7c4586f2",
    "question": "For a patient with newly diagnosed advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology and confirmed distant metastases, if comprehensive molecular profiling reveals no actionable driver mutations but PD-L1 expression is found to be 70%, which should take priority as the initial systemic therapy: PD-1/PD-L1 inhibitor monotherapy or platinum-based chemotherapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "In this clinical setting—advanced NSCLC, adenocarcinoma subtype, no actionable mutations, and high PD-L1 expression (≥50%)—PD-1/PD-L1 inhibitor monotherapy is prioritized as first-line systemic therapy over platinum-based chemotherapy, according to current evidence and guideline consensus.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_0efeaa2a035f",
    "question": "For a patient with newly diagnosed non-small cell lung cancer staged as T1–2, N3, is pathological confirmation of N3 status mandatory before proceeding to initial stage IIIB/IIIC treatment, or can imaging findings (e.g., FDG-PET/CT) alone suffice as evidence of N3 disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Nodes negative",
            "Treatment (NSCL-9)",
            "T1, N0",
            "Operable",
            "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
            "Adjuvant Treatment (NSCL-4)"
          ]
        }
      }
    ],
    "answer": "Pathological confirmation of N3 status is mandatory prior to initiating stage IIIB/IIIC therapy; imaging findings alone, such as FDG-PET/CT results, are insufficient for definitive staging, as histological proof is required to establish N3 disease and guide appropriate management.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_70dc47429727",
    "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology, who is confirmed to have an NTRK1 gene fusion and high PD-L1 expression (≥50%), which first-line systemic treatment should be prioritized: a selective TRK inhibitor or PD-1/PD-L1 immune checkpoint inhibitor monotherapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "NTRK1/2/3 gene fusion positive"
          ]
        }
      }
    ],
    "answer": "For advanced NSCLC with a confirmed NTRK1 fusion, first-line therapy should prioritize a selective TRK inhibitor, as targeted therapy demonstrates higher efficacy and response rates in oncogene-driven tumors. High PD-L1 expression does not supersede guideline-first targeted therapy when actionable oncogenic drivers are present.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3d863626ef35",
    "question": "In a patient with newly diagnosed stage IV, M1b non-small cell lung cancer (NSCLC) of adenocarcinoma subtype, is broad molecular profiling for EGFR, ALK, ROS1, BRAF, NTRK, MET exon 14 skipping, RET, and ERBB2 (HER2) still indicated if the patient is a never-smoker and presents with limited brain metastases but has not been tested previously?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Limited metastases",
            "Stage IV, M1b (NSCL-15)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Yes, comprehensive molecular profiling remains indicated regardless of smoking status and number or location of metastases, as actionable mutations may be present even in never-smokers with limited metastatic disease; this guides targeted therapy selection and is standard in advanced adenocarcinoma NSCLC.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3d7e36df50e1",
    "question": "In a patient with newly diagnosed stage IIIB non-small cell lung cancer (T1–2, N3) and a history of poor pulmonary function prohibiting surgery, is concurrent chemoradiation still a feasible definitive treatment option, or does poor lung function preclude this approach?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Poor pulmonary function significantly increases the risk of toxicity from concurrent chemoradiation and may contraindicate its use as a definitive treatment, as adequate lung reserve is required to tolerate combined modality therapy. In such cases, alternative strategies such as sequential chemoradiation, dose-modified regimens, or best supportive care should be considered based on functional assessment.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b427a8ac8171",
    "question": "For a patient with resected stage IIIA non-small cell lung cancer (T1–2, N2) who achieved R0 resection and completed adjuvant systemic therapy, if during surveillance a new small pulmonary nodule is detected without evidence of extrathoracic disease, is routine brain MRI with contrast warranted at this point?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Limited metastases",
            "Stage IV, M1b (NSCL-15)"
          ]
        }
      }
    ],
    "answer": "Routine brain MRI with contrast is not indicated in this scenario. Surveillance recommendations for resected stage III non-small cell lung cancer do not include brain MRI unless there are symptomatic findings or evidence of recurrence/metastasis. Brain MRI becomes appropriate only when recurrence or metastasis is suspected clinically or radiographically.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_75f84d613283",
    "question": "In a patient with stage IIIA non-small cell lung cancer characterized by resectable T4 tumor extension (N0-N1), is the recommendation for surgical resection predicated on the absence of distant metastases as confirmed by preoperative FDG-PET/CT and brain MRI?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Trachea/carina or mediastinum",
            "Treatment (NSCL-7)",
            "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
            "Surgery (preferred)",
            "Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "Yes, offering surgery as the preferred treatment for resectable stage IIIA (T4, N0–1) non-small cell lung cancer is contingent upon thorough preoperative staging—including FDG-PET/CT and brain MRI—to exclude the presence of distant metastases, ensuring the disease is truly resectable and localized.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_aba0c3bebadd",
    "question": "In patients with multiple lung cancers (N0–1) and a dominant nodule showing evidence of growth, if definitive local therapy is not feasible, does proceeding directly to palliative chemotherapy necessarily exclude the possibility of subsequent local palliative interventions such as laser, stent placement, or external-beam radiotherapy if locoregional recurrence or endobronchial obstruction occurs?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Multiple lung cancers (suspected or confirmed) (N0–1)",
            "Multidisciplinary evaluation",
            "Dominant nodule with evidence of growth",
            "Definitive local therapy not possible",
            "Palliative chemotherapy ± local palliative therapy or Observe",
            "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, initiating palliative chemotherapy in patients with unresectable multiple lung cancers (N0–1) does not preclude later use of local palliative measures like laser, stent, or external-beam radiotherapy if locoregional recurrence or symptomatic endobronchial obstruction develops; local interventions remain appropriate for symptomatic management.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ae43779eaf4c",
    "question": "For a patient with resectable Stage IA (peripheral T1abc, N0) non-small cell lung cancer who exhibits significant impairment on pulmonary function tests (PFTs), does surgical resection remain the recommended first-line treatment over non-surgical modalities such as stereotactic body radiotherapy (SBRT)?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "PS 3–4",
            "Systemic Therapy for Metastatic Disease (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "In patients with Stage IA (peripheral T1abc, N0) NSCLC and significant pulmonary dysfunction indicated by impaired PFTs, surgical resection may not be the preferred first-line treatment. Non-surgical modalities such as stereotactic body radiotherapy (SBRT) are prioritized due to increased perioperative risk, making SBRT the standard for surgically high-risk or medically inoperable patients.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_20be97c23913",
    "question": "In a patient with mediastinal lymph node recurrence of non-small cell lung cancer who has not received prior thoracic radiotherapy, is it appropriate to prioritize concurrent chemoradiation over immediate systemic therapy, assuming no evidence of disseminated disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Yes, in patients with mediastinal lymph node recurrence of NSCLC who have not previously received thoracic radiotherapy and lack evidence of distant metastases, concurrent chemoradiation is the preferred treatment over immediate systemic therapy, as it offers superior local control and potential survival benefit in this locoregional setting.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_94b4ff3b7084",
    "question": "In a patient with non-squamous non-small cell lung cancer and newly identified distant metastases, if molecular profiling is negative for actionable mutations but PD-L1 testing shows tumor proportion score ≥50%, should first-line systemic therapy prioritize immune checkpoint inhibitor monotherapy over platinum-based chemotherapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Yes; for metastatic non-squamous NSCLC lacking actionable mutations and with PD-L1 TPS ≥50%, first-line immune checkpoint inhibitor monotherapy is prioritized over platinum-based chemotherapy, consistent with current evidence and international treatment guidelines.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_cc75b4f6ce9f",
    "question": "In a patient with stage IVA non-small cell lung cancer characterized by a single contralateral pulmonary nodule (N0, M1a), if both lung tumors are considered individually resectable and there is no evidence of mediastinal nodal involvement or distant metastasis, should management proceed as two primary lung cancers rather than as metastatic disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treatment",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
          ]
        }
      }
    ],
    "answer": "Yes, in the scenario of stage IVA non-small cell lung cancer with a solitary contralateral pulmonary nodule and no mediastinal or distant metastases, if both tumors are deemed individually resectable, treatment should follow the approach for synchronous primary lung cancers rather than metastatic disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2ca605b7374c",
    "question": "In a patient with stage IVA, M1b squamous cell carcinoma of the lung who has an EGFR exon 19 deletion, is first-line treatment with osimertinib combined with pemetrexed and platinum chemotherapy appropriate, or is this regimen restricted to nonsquamous histology only?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "EGFR exon 19 deletion or exon 21 L858R mutation positive",
            "EGFR exon 19 deletion or exon 21 L858R mutations",
            "EGFR mutation discovered prior to first-line systemic therapy",
            "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
            "Progression, Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
          ]
        }
      }
    ],
    "answer": "The combination of osimertinib with pemetrexed and platinum chemotherapy is indicated specifically for EGFR-mutant nonsquamous non-small cell lung cancer. For squamous histology, this regimen is not recommended; EGFR-TKI monotherapy, such as osimertinib alone, is typically preferred if an EGFR mutation is present.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_8677599bbd68",
    "question": "In a patient with advanced non-small cell lung cancer (adenocarcinoma subtype) and newly diagnosed multiple bone metastases, but normal renal function and no evidence of impending pathological fracture, should bisphosphonate therapy or denosumab be prioritized over immediate palliative external-beam radiotherapy for bone-directed management?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Distant metastases",
            "Bone metastases",
            "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Immediate palliative external-beam radiotherapy is prioritized if there is risk of fracture or symptomatic bone metastases, aiming at pain control and local stabilization, while bisphosphonates or denosumab are primarily indicated to reduce skeletal-related events but do not replace the need for timely radiotherapy for symptomatic lesions.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f49df3daad40",
    "question": "For a patient with stage IIB (T3, N0) non-small cell lung cancer who underwent complete surgical resection but has positive margins (R1), is systemic therapy alone sufficient, or should chemoradiation (sequential or concurrent) be considered as the preferred option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
            "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "In stage IIB (T3, N0) NSCLC with R1 resection margins, chemoradiation—either sequential or concurrent—should be considered over systemic therapy alone, as radiotherapy is necessary to address residual microscopic disease at the surgical margin and reduce the risk of locoregional recurrence. Systemic therapy alone is not adequate in this context.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e51a8aa988e1",
    "question": "For a patient with stage IIA (T2b, N0) non–small cell lung cancer who has undergone R0 resection without adjuvant therapy, and subsequently develops locoregional mediastinal lymph node recurrence without prior radiotherapy, which is the preferred initial treatment: concurrent chemoradiation or systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIA (T2b, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Concurrent chemoradiation is the preferred initial treatment in this scenario. Locoregional mediastinal lymph node recurrence after R0 surgery, in the absence of previous radiotherapy, warrants definitive intent salvage chemoradiation rather than systemic therapy alone.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ee33c8f40b41",
    "question": "In a patient with non-inflammatory, non-metastatic invasive breast cancer, estrogen receptor-negative, progesterone receptor-negative, and HER2-negative subtype, tumor size greater than 1 cm, and with up to micrometastatic axillary lymph node involvement (pN1mi only), is adjuvant chemotherapy still indicated if the patient has significant cardiac comorbidity potentially increasing chemotherapy-related risk?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
            "ER-negative and PR-negative",
            "HER2-negative",
            "BINV-10",
            "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
            "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
            "Tumor >1 cm",
            "Adjuvant chemotherapy (category 1)",
            "Follow-Up (BINV-17)"
          ]
        }
      }
    ],
    "answer": "Although adjuvant chemotherapy is category 1 and generally indicated for ER-, PR-, HER2-negative breast cancers larger than 1 cm with pN0 or pN1mi, significant cardiac comorbidity may contraindicate certain chemotherapy regimens. Anthracyclines should be avoided in this context, and alternative regimens or omission of chemotherapy should be considered based on cardiac risk assessment.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9c2d09957799",
    "question": "In a patient with stage IB (T2a, N0) non–small cell lung cancer who has undergone complete surgical resection with negative margins (R0), and is currently free of clinical or radiographic evidence of disease, does the recommendation for routine brain MRI during surveillance implicitly assume a high risk of CNS relapse, or is brain MRI not routinely indicated in this scenario?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (T2a, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Routine brain MRI is not indicated for surveillance in stage IB (T2a, N0) non–small cell lung cancer patients after complete resection when there is no clinical or radiographic evidence of recurrence; such imaging is not routinely recommended in the absence of symptoms or higher-stage disease, as the assumed risk of CNS relapse in this context is low.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_683f88394ba4",
    "question": "In a patient with a separate pulmonary nodule located in an ipsilateral non-primary lobe (classified as T4, N0–1), is surgical resection appropriate as an initial treatment in the absence of planned preoperative systemic therapy, or should induction systemic therapy be prioritized before surgery?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treatment",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
            "Surgery after preoperative systemic therapy, if planned",
            "N2",
            "Margins positive",
            "R1",
            "Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "For a separate pulmonary nodule in an ipsilateral non-primary lobe (T4, N0–1), surgical resection may be considered; however, induction systemic therapy prior to surgery is generally preferred to optimize disease control. Proceeding directly to surgery without preoperative systemic therapy is less favored in this clinical context.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f239207910ff",
    "question": "In a patient with advanced non-small cell lung cancer (NSCLC), histologically confirmed adenocarcinoma, and diffuse brain metastases, who tests positive for NTRK1 gene fusion, should an NTRK inhibitor be prioritized over conventional palliative external-beam radiotherapy for management of brain lesions?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "NTRK1/2/3 gene fusion positive"
          ]
        }
      }
    ],
    "answer": "For advanced NSCLC with diffuse brain metastases and confirmed NTRK1 gene fusion, an NTRK inhibitor is generally prioritized due to its systemic efficacy, including intracranial activity. However, if brain lesions are causing severe neurological symptoms or mass effect, urgent palliative radiotherapy may be necessary before initiating targeted therapy.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_32957d6176f2",
    "question": "In a patient with advanced non-small cell lung cancer (NSCLC) histologically classified as adenocarcinoma, large cell carcinoma, or NSCLC not otherwise specified, with confirmed BRAF V600E mutation, should BRAF-targeted therapy be considered if the patient has a significant history of prior thoracic radiotherapy and ongoing palliative care needs?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "BRAF V600E mutation positive"
          ]
        }
      }
    ],
    "answer": "Yes. The presence of a BRAF V600E mutation in advanced NSCLC indicates eligibility for BRAF-targeted therapy, such as a BRAF inhibitor (± MEK inhibitor), regardless of prior thoracic radiotherapy or concurrent palliative care requirements, provided overall clinical status permits systemic treatment.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_44c4de2a1922",
    "question": "For a 72-year-old man with a 20 pack-year smoking history and stable solid pulmonary nodule measuring 5 mm on chest CT, complicated by underlying pulmonary fibrosis, is it appropriate to discontinue routine imaging follow-up after 12 months of stability?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Incidental finding of nodule suspicious for lung cancer",
            "Multidisciplinary evaluation, Smoking cessation counseling",
            "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
            "Solid nodules Follow-up (DIAG-2)",
            "Incidental finding: solid nodule(s) on chest CT",
            "High risk",
            "< 6 mm CT at 12 mo (optional)",
            "Stable No routine follow-up"
          ]
        }
      }
    ],
    "answer": "No; in patients with high-risk factors such as extensive smoking history and underlying pulmonary fibrosis, discontinuing imaging follow-up solely based on nodule stability for 12 months is not appropriate, as their risk of malignancy remains elevated regardless of nodule size.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2db4b1578be6",
    "question": "In a patient with stage II non-small cell lung cancer who underwent surgical resection but has positive surgical margins (R1), is it justified to proceed directly to surveillance without additional chemoradiation or systemic therapy if there is no residual radiographic evidence of disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
            "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Severe hemoptysis",
            "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "No, it is not justified. The presence of positive surgical margins (R1) after resection in stage II non-small cell lung cancer indicates a higher risk of local recurrence, and standard practice requires consideration of additional systemic therapy or chemoradiation before proceeding to surveillance, even if no residual disease is radiographically evident.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f7bfb30f7c7c",
    "question": "In a patient with stage IA non-small cell lung cancer (T1abc, N0) who undergoes surgical resection but is found to have positive margins (R1 or R2), does the recommendation for re-resection or adjuvant radiotherapy implicitly require the absence of distant metastasis at the time of decision-making?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, the consideration of re-resection or adjuvant radiotherapy for stage IA non-small cell lung cancer with positive margins is predicated on the disease being localized without evidence of distant metastasis. The presence of metastatic disease would shift management toward systemic therapy rather than local interventions.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_5071fc6c8a45",
    "question": "For a patient with non-small cell lung cancer presenting with a separate pulmonary nodule in the same lobe as the primary tumor, staged as T3N0, is surgical resection still an appropriate treatment option, or does the presence of this additional nodule alter the indications for surgery?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
            "Surgery after preoperative systemic therapy, if planned",
            "N2",
            "Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "Surgical resection remains an appropriate treatment for non-small cell lung cancer staged as T3N0 due to a separate pulmonary nodule within the same lobe, as this presentation falls within the criteria for surgery and does not in itself exclude resectability.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c08d944f95fb",
    "question": "In a patient with advanced squamous cell carcinoma of the lung and confirmed NTRK1/2/3 gene fusion, is the primary indication for initiating an NTRK-targeted therapy dependent on the absence of other actionable driver mutations such as EGFR, ALK, or ROS1?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "NTRK1/2/3 gene fusion positive"
          ]
        }
      }
    ],
    "answer": "Yes. NTRK inhibitor therapy is indicated for tumors with NTRK fusions, but only when no alternate approved actionable driver mutations (such as EGFR, ALK, or ROS1) are present, as NTRK inhibitors are reserved for cases lacking other targetable alterations with established first-line therapies.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1658c5caf59e",
    "question": "For a patient with stage I non-small cell lung cancer who has undergone surgical resection but whose surgical margins are positive (R1 or R2), is surveillance with regular chest CT imaging a sufficient post-operative strategy, or is additional local treatment always indicated?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (T2a, N0); Margins positive (R1, R2)",
            "Resection (preferred) ± systemic therapy or RT",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Surveillance alone is not sufficient for a stage I non-small cell lung cancer patient with positive surgical margins (R1 or R2) after resection. Additional local treatment, such as re-resection or radiotherapy, is generally indicated to address the residual disease risk before initiating routine surveillance imaging.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_14bd8645a3d1",
    "question": "In a newly diagnosed metastatic non-small cell lung cancer (NSCLC) patient with adenocarcinoma histology and confirmed EGFR S768I mutation detected before any systemic therapy, both afatinib and first-generation EGFR tyrosine kinase inhibitors (TKIs) like gefitinib or erlotinib are potentially active options. Which agent should be prioritized according to optimal first-line therapy selection for this specific EGFR mutation, and what is the rationale?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "EGFR S768I, L861Q, and/or G719X mutation positive",
            "EGFR S768I, L861Q, and/or G719X mutations",
            "EGFR mutation discovered prior to first-line systemic therapy",
            "Preferred: Afatinib",
            "Progression",
            "Subsequent Therapy (NSCL-23)"
          ]
        }
      }
    ],
    "answer": "Afatinib should be prioritized as first-line therapy for NSCLC patients harboring EGFR S768I mutation, as clinical evidence demonstrates superior activity of afatinib against rare EGFR mutations like S768I compared to first-generation TKIs. This recommendation aligns with the preferred regimen for these specific non-classical mutations.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_fadeeb7f992d",
    "question": "In a patient with localized invasive breast cancer who presents with suspicious axillary lymph nodes on imaging, if the initial ultrasound-guided core biopsy of the most suspicious node is negative for malignancy, does the presence of clinical suspicion or imaging abnormality still necessitate axillary lymph node dissection, or is sentinel lymph node mapping and excision alone sufficient?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS possible",
            "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
            "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
            "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
            "FNA or core biopsy negative",
            "SLN mapping and excision",
            "SLN negative",
            "No further axillary surgery (category 1)"
          ]
        }
      }
    ],
    "answer": "If ultrasound-guided core biopsy of the most suspicious axillary node is negative for malignancy, sentinel lymph node (SLN) mapping and excision alone is sufficient; axillary lymph node dissection (ALND) is not indicated, even when clinical or imaging findings are suspicious.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_aba101df4d7f",
    "question": "For a patient with stage IIIB non-small cell lung cancer (T2, N3) and no evidence of extrathoracic metastatic disease, is initial pathologic confirmation of N3 disease with mediastinoscopy or EBUS biopsy an implicit prerequisite for subsequent treatment planning, or can imaging studies alone suffice?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Pathologic confirmation of N3 disease—such as by mediastinoscopy or EBUS biopsy—is an essential prerequisite before treatment planning in stage IIIB (T2, N3) non-small cell lung cancer. Imaging studies alone are insufficient, as tissue confirmation is required to accurately assign stage and select appropriate therapy.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3915d4e015c3",
    "question": "In a patient with stage IVA, metastatic squamous cell carcinoma of the lung who is confirmed ALK rearrangement positive prior to first-line therapy, is broad molecular profiling still a prerequisite before starting ALK inhibitor treatment, or can targeted therapy be initiated based solely on the ALK result?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "ALK rearrangement positive",
            "ALK rearrangement",
            "ALK rearrangement discovered prior to first-line systemic therapy",
            "Useful in Certain Circumstances Crizotinibb (category 1)",
            "Progression",
            "Subsequent Therapy (NSCL-29)"
          ]
        }
      }
    ],
    "answer": "Initiation of ALK inhibitor therapy such as crizotinib is appropriate as first-line treatment in an ALK-rearranged squamous cell carcinoma once the ALK rearrangement is confirmed. Although comprehensive molecular profiling is recommended, the presence of an actionable ALK alteration is sufficient to proceed without delay for additional molecular results.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_8f202e38254d",
    "question": "For a patient with stage I non–small cell lung cancer (NSCLC) who received primary treatment consisting solely of surgery, if persistent, unexplained radiographic abnormalities appear during routine follow-up, is more frequent imaging required even in the absence of symptoms?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
            "R1; Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Severe hemoptysis",
            "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, in the presence of residual or new radiographic abnormalities during follow-up after surgery for stage I NSCLC, more frequent imaging is warranted to promptly detect recurrence or progression, regardless of the presence of symptoms. Regular surveillance intervals may not be sufficient in this scenario.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_73b723595dc6",
    "question": "For a patient with stage IIIA non-small cell lung cancer (defined as T1-2, N2) who underwent surgical resection with positive margins (R1 resection), is adjuvant chemoradiation implicitly based on the assumption of no evidence of distant metastases on postoperative imaging?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
            "R1; Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Limited metastases",
            "Stage IV, M1b (NSCL-15)"
          ]
        }
      }
    ],
    "answer": "Yes, the use of adjuvant chemoradiation after R1 resection in stage IIIA non-small cell lung cancer is predicated on the absence of distant metastases on postoperative imaging. The therapeutic intent is curative local control; the presence of metastases would instead shift management toward systemic therapy for advanced disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_8cf4c1464287",
    "question": "In a patient with stage IA (peripheral T1abc, N0) non-small cell lung cancer and severely impaired pulmonary function as demonstrated by pulmonary function tests, is surgical resection still the preferred primary treatment modality over external-beam radiotherapy or stereotactic ablative radiotherapy (SABR)?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "No, in patients with stage IA (peripheral T1abc, N0) non-small cell lung cancer who have severely impaired pulmonary function, surgical resection is not preferred. Instead, external-beam radiotherapy or stereotactic ablative radiotherapy (SABR) becomes the primary local treatment modality due to the increased perioperative risk associated with surgery.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9f4c36b8f72b",
    "question": "In patients with operable, non-inflammatory, non-metastatic (M0) HER2-positive breast cancer staged as cT1c, cN0, is it appropriate to initiate preoperative systemic therapy if the tumor is also triple-negative, and how does this impact the prioritization of preoperative therapy versus immediate surgery?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS possible",
            "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
            "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
            "HR-positive/ HER2-positive",
            "ypT1–4,N0 or ypN≥1",
            "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
          ]
        }
      }
    ],
    "answer": "For both cT1c, cN0, HER2-positive and cT1c, cN0, triple-negative breast cancer, preoperative systemic therapy is a recommended option given the higher recurrence risk and potential for downstaging, and it should be prioritized over immediate surgery to maximize systemic control and assess tumor response.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_392c48da550d",
    "question": "For a patient with clinical stage cT1c, cN0 triple-negative breast cancer who is being considered for preoperative systemic therapy, if baseline liver function tests reveal significant hepatic impairment, is standard preoperative systemic chemotherapy still generally recommended in this scenario?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
            "Preoperative systemic therapy see BINV-M 1",
            "No response to preoperative systemic therapy and/or tumor remains inoperable",
            "Consider additional systemic therapy and/or preoperative radiation",
            "Response to preoperative systemic therapy and tumor is operable",
            "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
            "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
            "HR-negative/ HER2-positive",
            "ypT1–4,N0 or ypN≥1",
            "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
          ]
        }
      }
    ],
    "answer": "No, standard preoperative systemic chemotherapy for triple-negative breast cancer requires adequate hepatic function. Significant hepatic impairment is a contraindication to most standard regimens due to increased risk of toxicity; alternative approaches or dose modifications must be considered, and treatment may need to be postponed until liver function improves.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_01f560e8bb15",
    "question": "In a patient with biopsy-proven synchronous pulmonary nodules located in the same lobe, classified as T3N0–1, how would the discovery of a positive mediastinal lymph node impact the initial management strategy compared to cases with confirmed N0–1 status?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
            "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "No disease outside of chest",
            "Pathologic mediastinal lymph node evaluation",
            "N0–1",
            "Initial Treatment (NSCL-12)"
          ]
        }
      }
    ],
    "answer": "The presence of a positive mediastinal lymph node would upstage the disease from T3N0–1 to at least stage IIIA, which necessitates additional mediastinal evaluation and consideration of multimodal perioperative therapy, rather than proceeding directly to surgical management as might be considered for T3N0–1 without mediastinal involvement.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2282759c3b2f",
    "question": "In patients with advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma subtype who are confirmed to have an ERBB2 (HER2) mutation, does the use of fam-trastuzumab deruxtecan-nxki as a preferred systemic therapy option implicitly require positive ERBB2 (HER2) mutation status, or can it reasonably be considered for patients lacking this molecular alteration?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "ERBB2 (HER2) mutation positive",
            "ERBB2 (HER2) mutation",
            "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
            "Tumor response evaluation",
            "Response or stable disease",
            "4–6 cycles (total)",
            "Tumor response evaluation",
            "Response or stable disease",
            "Maintenance therapy",
            "Progression",
            "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
            "Progression",
            "PS 3–4",
            "Best supportive care: NCCN Guidelines for Palliative Care"
          ]
        }
      }
    ],
    "answer": "The use of fam-trastuzumab deruxtecan-nxki as a preferred systemic therapy requires confirmed ERBB2 (HER2) mutation positivity; it is not indicated for patients without this mutation. The selection of this agent is specifically predicated on the presence of the ERBB2 (HER2) genetic alteration.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_7a5dba4ba929",
    "question": "In a patient with localized, invasive, non-metastatic (M0), HR-positive, HER2-positive breast cancer who undergoes preoperative systemic therapy and subsequently achieves a pathological complete response (ypT0N0), is completion of 1 year of HER2-directed therapy with trastuzumab still indicated, or does the absence of residual disease allow omission of targeted therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS not possible",
            "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
            "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
            "HR-positive/ HER2-positive",
            "ypT0N0 or pCR",
            "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
          ]
        }
      }
    ],
    "answer": "Completion of 1 year of HER2-directed therapy with trastuzumab remains indicated, regardless of achieving a pathological complete response (ypT0N0) after preoperative systemic therapy in HR-positive, HER2-positive, non-metastatic breast cancer. The absence of residual disease does not warrant omission of HER2-targeted therapy.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c8a36d5e50dc",
    "question": "In a patient with advanced squamous cell carcinoma of the lung, if a MET exon 14 skipping mutation is identified prior to the initiation of systemic therapy, but concurrent severe hepatic impairment is present, is capmatinib or tepotinib therapy still considered an appropriate first-line treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "METex14 skipping mutation positive",
            "METex14 skipping mutation",
            "METex14 skipping mutation discovered prior to first-line systemic therapy",
            "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
            "Progression",
            "Preferred Capmatinib or Tepotinib",
            "Progression",
            "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
          ]
        }
      }
    ],
    "answer": "Capmatinib and tepotinib are standard first-line targeted therapies for advanced NSCLC with MET exon 14 skipping mutations. However, in the presence of severe hepatic impairment, both agents are relatively contraindicated due to their hepatic metabolism and potential toxicity, and alternative treatment approaches should be considered.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_40ba96328dae",
    "question": "In a patient diagnosed with stage IVA non-small cell lung cancer (NSCLC) presenting as a solitary nodule in the contralateral lung (N0, M1a), can these lesions be managed as two curable primary lung tumors if both are deemed technically resectable, or does the presence of M1a disease status exclude this approach?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treatment",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
            "Pathologic Diagnosis of NSCLC",
            "Initial Evaluation",
            "H&P (include performance status + weight loss)"
          ]
        }
      }
    ],
    "answer": "If both the primary tumor and the contralateral solitary lung nodule in a stage IVA (N0, M1a) NSCLC patient are technically resectable and considered curable, they can be managed as two primary lung tumors. The M1a designation due to a single contralateral nodule does not preclude the curative intent multimodal management in this specific scenario.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c3b924d50147",
    "question": "In a patient diagnosed with non-small cell lung cancer, if two pulmonary nodules are detected in different ipsilateral lobes, both staged as T4, N0–1, does this clinical scenario still allow for surgical intervention as a primary treatment approach, or does it necessitate an immediate transition to systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
            "Pathologic Diagnosis of NSCLC",
            "Clinical Stage",
            "Stage IB, peripheral (T2a, N0); Stage I, central (T1abc–T2a, N0); Stage II (T1abc–T2ab, N1; T2b, N0); Stage IIB (T3, N0)f; Stage IIIA (T3, N1)",
            "Pretreatment Evaluation (NSCL-3)"
          ]
        }
      }
    ],
    "answer": "When two pulmonary nodules are located in different ipsilateral lobes and staged as T4, N0–1, surgical resection remains a viable primary treatment option if both lesions are deemed potentially curable. Systemic therapy is not mandated solely by the presence of two ipsilateral nodules; curative-intent surgery should be considered if resectability criteria are fulfilled.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_6228c555007b",
    "question": "For a patient with operable non-small cell lung cancer staged as T1, N0 who undergoes complete surgical resection with negative margins, is postoperative adjuvant therapy routinely indicated, or is surveillance considered sufficient in the absence of high-risk pathological features?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Nodes negative",
            "Treatment (NSCL-9)",
            "T1, N0",
            "Operable",
            "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
            "Adjuvant Treatment (NSCL-4)",
            "Stage IIA (T2b, N0); Margins positive (R1, R2)",
            "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "In operable non-small cell lung cancer patients with T1, N0 staging and complete resection with negative margins, adjuvant therapy is not routinely indicated; surveillance alone is considered sufficient unless additional high-risk pathological features are identified.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b8d73b9f1b04",
    "question": "In a patient with advanced squamous non-small cell lung cancer presenting with Stage IVA, M1b disease and a performance status of 3–4, who is confirmed negative for actionable molecular alterations and has PD-L1 expression less than 1%, is there any indication for initial systemic therapy over best supportive care?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above",
            "PD-L1 <1%",
            "INITIAL SYSTEMIC THERAPY",
            "PS 3–4",
            "Best supportive care NCCN Guidelines for Palliative Care"
          ]
        }
      }
    ],
    "answer": "No, in the setting of advanced squamous NSCLC with Stage IVA, M1b, poor performance status (PS 3–4), absence of actionable molecular biomarkers, and PD-L1 <1%, the recommended approach is best supportive care; initial systemic therapy is not indicated regardless of other factors.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_0800e21861f9",
    "question": "In a patient with stage II non-small cell lung cancer who is medically inoperable and has a history of significant restrictive lung disease demonstrated by poor pulmonary function tests, is stereotactic ablative radiotherapy (SABR) still preferred as the definitive treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "No nodal disease",
            "Medically inoperable, high surgical risk as determined by thoracic surgeon, and those who decline surgery after thoracic surgical consultation",
            "Definitive RT, preferably SABR",
            "Consider adjuvant chemotherapy for high-risk stage II",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)"
          ]
        }
      }
    ],
    "answer": "Yes, stereotactic ablative radiotherapy (SABR) remains the preferred definitive treatment for stage II non-small cell lung cancer in medically inoperable patients, including those with significant restrictive lung disease, as surgery is contraindicated. SABR provides effective local control while minimizing pulmonary toxicity compared to conventional radiotherapy.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ef1cf930bc18",
    "question": "In a patient with non-small cell lung cancer presenting with a separate pulmonary nodule and mediastinal lymph node involvement, would the indication for perioperative therapy implicitly assume that the patient has Stage IIIA or higher disease, and thereby exclude Stage IIB cases?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, the indication for perioperative therapy in the setting of a separate pulmonary nodule encompasses both Stage IIB and higher stages, such as IIIA and IV, and does not exclude Stage IIB patients. The presence of a separate nodule necessitates evaluation for advanced locoregional treatment regardless of whether the disease is classified as Stage IIB or above.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2373666236c2",
    "question": "For a patient with completely resected stage IIB non-small cell lung cancer (NSCLC) who received both surgery and postoperative chemotherapy, but who has chronic kidney disease precluding the use of intravenous contrast, is low-dose non–contrast-enhanced chest CT sufficient for routine surveillance in the first two years after treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, for stage I–II NSCLC patients who have completed primary treatment with surgery ± chemotherapy and have contraindications to intravenous contrast, low-dose non–contrast-enhanced chest CT combined with history and physical examination is a sufficient routine surveillance modality in the first two years, as contrast enhancement is optional rather than mandatory in this context.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1c63866025ab",
    "question": "In a patient with stage IIIA NSCLC (T1–2, N2) who has a history of prior thoracic radiotherapy, is locoregional recurrence involving mediastinal lymph nodes still an absolute indication for repeat radiotherapy, or is systemic therapy preferred in this context?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "For patients with stage IIIA NSCLC (T1–2, N2) who have previously received thoracic radiotherapy and develop locoregional recurrence involving mediastinal lymph nodes, systemic therapy is preferred over repeat radiotherapy due to cumulative toxicity risks. Repeat radiotherapy is generally not indicated unless strictly individualized.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f02ed6899127",
    "question": "For a patient with squamous cell carcinoma of the lung who has a mediastinal lymph node recurrence after prior radiotherapy, and whose tumor is PD-L1 positive (≥1%) but negative for actionable molecular biomarkers, should broad molecular profiling still be performed, or is PD-L1 testing alone sufficient to guide systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
          ]
        }
      }
    ],
    "answer": "Broad molecular profiling remains indicated even in PD-L1 positive squamous cell carcinoma with negative initial actionable biomarkers, as additional genomic alterations may emerge, especially after prior treatment. Comprehensive molecular testing ensures optimal identification of potential targetable mutations critical for systemic therapy selection.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_5aff1bda8d18",
    "question": "In patients with stage I–II non-small cell lung cancer who have undergone primary treatment including surgical resection with positive margins (R1 or R2), does the surveillance protocol involving H&P and chest CT every 6 months for 2–3 years, followed by annual low-dose chest CT, also apply to those who received adjuvant radiotherapy after surgery?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (T2a, N0); Margins positive (R1, R2)",
            "Resection (preferred) ± systemic therapy or RT",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, the described surveillance protocol applies to stage I–II patients treated with surgery, regardless of whether adjuvant radiotherapy was administered postoperatively; the imaging intervals do not change due to the addition of radiotherapy in this context.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f9d618795547",
    "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma subtype, who has recurrence in mediastinal lymph nodes after prior radiotherapy, and whose tumor tests negative for EGFR, ALK, ROS1, and other actionable driver mutations, as well as PD-L1 expression less than 1%, is immunotherapy alone an appropriate initial systemic treatment option, or should chemotherapy be prioritized?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above"
          ]
        }
      }
    ],
    "answer": "For advanced non-small cell lung cancer of adenocarcinoma subtype with negative actionable mutations and PD-L1 expression less than 1%, immunotherapy alone is not recommended. In this setting, platinum-based chemotherapy, either alone or in combination with immunotherapy, should be prioritized as initial systemic treatment according to standard clinical practice.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_6c1fd9579dae",
    "question": "For a patient with non-small cell lung cancer presenting with a solitary nodule in the contralateral lung (TNM stage IVA, N0, M1a), under what condition can the disease be managed as two primary lung tumors instead of metastatic disease, and what is the clinical significance of this distinction?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treatment",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
          ]
        }
      }
    ],
    "answer": "If both lung tumors are deemed technically resectable and potentially curable based on comprehensive staging and evaluation, the disease can be managed as two primary lung cancers rather than as metastatic (stage IV) disease. This distinction is clinically significant because it allows for curative-intent local treatments, as opposed to palliative systemic therapy typically used for metastatic disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_13defc96483f",
    "question": "For a patient with resectable stage IIIA non-small cell lung cancer (NSCLC) and positive mediastinal lymph nodes following pathologic evaluation, does the recommendation for perioperative therapy implicitly require that no evidence of distant metastases has been identified by FDG-PET/CT and brain MRI with contrast?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, the recommendation for perioperative therapy in resectable stage IIIA NSCLC with positive mediastinal lymph nodes is predicated on the absence of distant metastatic disease on FDG-PET/CT and brain MRI. Detection of metastases would redirect management toward systemic therapy rather than local or perioperative interventions.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b8cb06a47185",
    "question": "In patients with stage IVA non–small cell lung cancer presenting with a malignant pleural effusion and confirmed EGFR exon 20 insertion mutation, is immune checkpoint inhibitor monotherapy a preferred first-line option over targeted therapy when broad molecular profiling has been performed?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1a: pleural or pericardial effusion",
            "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
            "Positive",
            "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "EGFR exon 20 insertion mutation positive"
          ]
        }
      }
    ],
    "answer": "No, for stage IVA non–small cell lung cancer with a confirmed EGFR exon 20 insertion mutation, targeted therapy specifically addressing the EGFR exon 20 alteration is preferred over immune checkpoint inhibitor monotherapy as first-line treatment, assuming broad molecular profiling has identified this actionable mutation.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_7826e8a7c2bc",
    "question": "For an adult patient with an incidentally detected solitary pure ground-glass pulmonary nodule measuring 5 mm in diameter on chest CT, but with a history of immunosuppression due to organ transplantation, is routine imaging follow-up still unnecessary according to standard nodule management boundaries?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Incidental finding of nodule suspicious for lung cancer",
            "Multidisciplinary evaluation, Smoking cessation counseling",
            "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
            "Subsolid nodules Follow-up (DIAG-3)",
            "Incidental finding: subsolid nodule(s) on chest CT",
            "Solitary pure ground-glass nodules",
            "<6 mm No routine follow-up"
          ]
        }
      }
    ],
    "answer": "No, in immunosuppressed patients, even pure ground-glass nodules smaller than 6 mm may warrant individualized evaluation and potentially closer surveillance, since immunosuppression increases the risk of both infection and malignancy, and standard management thresholds may not apply.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3cc5f4f8bf3c",
    "question": "In a patient with pure tubular breast carcinoma that is ER-positive, HER2-negative, tumor size 2.7 cm, and axillary staging showing pN1mi (axillary node metastasis ≤2 mm), does considering adjuvant endocrine therapy implicitly require the presence of invasive disease features beyond the favorable histology and hormone receptor expression?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
            "ER-positive and/or PR-positive or ER-negative and PR-negative",
            "Favorable Histologies (BINV-11)",
            "Pure tubular • Pure mucinous • Pure cribriform",
            "ER-positive and/or PR-positive, HER2-negative",
            "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
            "1–2.9 cm",
            "Consider adjuvant endocrine therapy",
            "Follow-Up (BINV-17)"
          ]
        }
      }
    ],
    "answer": "No; recommending adjuvant endocrine therapy in this scenario relies on the presence of hormone receptor positivity and acceptable nodal status, not on any disease features beyond the specified favorable histology, ER-positivity, HER2-negativity, tumor size, and pN1mi involvement.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_7fce1d3cd9ab",
    "question": "For a patient with non-small cell lung cancer presenting with superior vena cava (SVC) obstruction and no evidence of disseminated metastatic disease, is concurrent chemoradiation preferred over external-beam radiotherapy alone if the patient has not previously received chemoradiation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Yes, for non-small cell lung cancer patients with SVC obstruction and no prior chemoradiation, concurrent chemoradiation is the preferred treatment over external-beam radiotherapy alone, as it offers improved local control and potential survival benefit in the absence of disseminated disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_685430237405",
    "question": "In a patient with stage IIIB (T1–2, N3) non-small cell lung cancer (NSCLC) who has not yet undergone pulmonary function testing or mediastinal lymph node pathological confirmation, is it appropriate to proceed directly to systemic therapy based solely on imaging findings of N3 nodal involvement?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, it is not appropriate. Pathological confirmation of N3 disease is required before systemic therapy initiation in stage IIIB NSCLC, as imaging findings alone are insufficient to guide definitive treatment decisions. Pulmonary function testing is also necessary for comprehensive pre-treatment assessment.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b8224c49b40d",
    "question": "In a patient diagnosed with non-small cell lung cancer staged as T1–3, N2, M0, if mediastinal lymph node involvement is confirmed, does the recommendation for systemic therapy with or without radiotherapy require the patient to be without distant metastases for eligibility?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "N1 or N2 nodes positive, M0",
            "Treatment (NSCL-10)",
            "Mediastinal Biopsy Findings",
            "T1–3, N2 nodes positive, M0",
            "Systemic therapy ± RT",
            "Progression",
            "Local: RT (if feasible) ± chemotherapy"
          ]
        }
      }
    ],
    "answer": "Yes, the use of systemic therapy with or without radiotherapy in T1–3, N2, M0 non-small cell lung cancer is predicated on the absence of distant metastases (M0). If distant metastases are present (M1), this treatment approach is no longer appropriate and systemic therapy alone for metastatic disease should be considered.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_5968928944de",
    "question": "In a patient with stage IIIB non-small cell lung cancer presenting with T3N2 disease, is the evaluation for perioperative therapy contingent upon confirmation that there are no distant metastases on FDG-PET/CT and brain MRI with contrast?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Distant metastases",
            "Bone metastases",
            "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, perioperative therapy evaluation in stage IIIB (T3N2) non-small cell lung cancer presumes the absence of distant metastases, as confirmed by FDG-PET/CT and brain MRI with contrast. Presence of metastases would shift management to systemic or palliative therapies rather than perioperative interventions.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_0f4b291d019c",
    "question": "A chest CT reveals multiple subsolid pulmonary nodules, with the most suspicious nodule measuring precisely 6 mm in greatest diameter. Is an initial follow-up CT scan at 3–6 months still indicated, or does the 6 mm threshold represent an exclusion for this surveillance strategy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Incidental finding of nodule suspicious for lung cancer",
            "Multidisciplinary evaluation, Smoking cessation counseling",
            "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
            "Subsolid nodules Follow-up (DIAG-3)",
            "Incidental finding: subsolid nodule(s) on chest CT",
            "Multiple subsolid nodules",
            "≥6 mm • CT at 3–6 mo • Subsequent management based on most suspicious nodule(s)"
          ]
        }
      }
    ],
    "answer": "An initial follow-up CT scan at 3–6 months is still indicated when the most suspicious subsolid pulmonary nodule measures exactly 6 mm. The ≥6 mm threshold includes nodules that are precisely 6 mm, not excluding them from recommended surveillance.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_313d70db8c42",
    "question": "For a patient with non-small cell lung cancer who has no evidence of disease after initial surgery and chemotherapy for stage II disease, is routine use of FDG-PET/CT appropriate during the first three years of surveillance if there is no clinical or radiographic suspicion of recurrence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "No, routine use of FDG-PET/CT is not appropriate in this scenario. In asymptomatic patients with no evidence of recurrence on regular assessment following curative-intent treatment for stage I–II disease, standard surveillance includes history, physical examination, and chest CT imaging only. FDG-PET/CT should be reserved for evaluation when recurrence is suspected.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_5a582543df54",
    "question": "In a patient with stage IIIB (T3, N2) non-small cell lung cancer who previously received thoracic radiotherapy and now presents with mediastinal lymph node recurrence without evidence of distant metastases, is concurrent chemoradiation an appropriate therapeutic option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Concurrent chemoradiation is not appropriate in this scenario, as prior thoracic radiotherapy is a relative contraindication for repeat concurrent chemoradiation due to increased risk of cumulative toxicity; alternative approaches such as systemic therapy or observation should be considered.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f6fc4149b8bc",
    "question": "For a patient with stage IIIA non-small cell lung cancer (T3N1), is mediastinal lymph node pathologic evaluation mandatory prior to perioperative treatment initiation, or can imaging alone sufficiently guide management decisions?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Pathologic confirmation of mediastinal lymph node status is mandatory before perioperative treatment in stage IIIA (T3N1) non-small cell lung cancer. Imaging alone does not provide sufficient diagnostic certainty for N status; tissue confirmation (e.g., mediastinoscopy, EBUS) is required to accurately guide further management.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9e2cd887c28c",
    "question": "In a patient with stage II non-small cell lung cancer (T1abc–2ab, N1 or T2b, N0) and known significantly reduced pulmonary function on preoperative pulmonary function tests (PFTs), is surgical resection still a recommended treatment option, or should alternative local therapies such as external-beam radiotherapy or stereotactic ablative radiotherapy (SABR) be prioritized due to increased perioperative risk?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "For stage II non-small cell lung cancer patients with significantly impaired pulmonary function demonstrated on PFTs, surgical resection is typically contraindicated due to a high risk of perioperative complications. In such cases, alternative local therapies—external-beam radiotherapy or stereotactic ablative radiotherapy (SABR)—are prioritized as curative-intent treatments.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_95ca7742f78a",
    "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete surgical resection (R0), if follow-up chest imaging reveals equivocal small pulmonary nodules but no clear radiographic evidence of recurrence, does the recommended surveillance protocol mandate the use of routine FDG-PET/CT or brain MRI with contrast for further assessment at this stage?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIA (T2b, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, in the absence of clinical or definitive radiographic evidence of disease recurrence after R0 resection for stage IIA (T2b, N0) NSCLC, routine FDG-PET/CT and brain MRI with contrast are not indicated during surveillance; these modalities are reserved for evaluating suspected recurrence, not for routine follow-up in asymptomatic patients.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b0aded01b591",
    "question": "In a patient with advanced or metastatic non-small cell lung cancer (adenocarcinoma, large cell, or NSCLC not otherwise specified), whose tumor demonstrates PD-L1 expression less than 1% and is negative for all listed actionable molecular biomarkers, does the absence of EGFR, ALK, ROS1, BRAF, KRAS, NTRK, METex14, RET, and ERBB2 (HER2) mutations unequivocally indicate that targeted therapy is not appropriate as initial systemic treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above"
          ]
        }
      }
    ],
    "answer": "Yes, in this clinical setting, the absence of actionable alterations in EGFR, ALK, ROS1, BRAF, KRAS, NTRK, METex14, RET, and ERBB2 (HER2), along with PD-L1 expression less than 1%, means that targeted therapy agents directed at these mutations are not indicated for initial systemic treatment; standard management would proceed with non-targeted therapy options such as platinum-based chemotherapy or immunotherapy, as per current guidelines.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_64b5df459c27",
    "question": "In a patient with stage II non–small cell lung cancer who underwent definitive radiotherapy as primary treatment and currently shows no evidence of disease on imaging, is it appropriate to perform routine FDG-PET/CT or brain MRI during surveillance if the patient remains asymptomatic?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "No, routine FDG-PET/CT and brain MRI are not indicated for surveillance in asymptomatic patients with stage II non–small cell lung cancer after definitive radiotherapy. Surveillance should rely on clinical evaluation and periodic chest CT, reserving advanced imaging for situations involving new symptoms or radiographic abnormalities.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_da1940eb8c48",
    "question": "In a patient with advanced non-squamous non-small cell lung cancer (NSCLC) who has confirmed ALK rearrangement and concurrent bone metastases at risk of pathological fracture, should systemic ALK-targeted therapy be initiated before orthopedic stabilization and palliative radiotherapy, or is priority given to immediate local management of the bone lesion?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Bone metastases",
            "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "ALK rearrangement positive"
          ]
        }
      }
    ],
    "answer": "Immediate local management, including orthopedic stabilization and palliative radiotherapy, takes priority in the setting of bone metastases at high risk of fracture or spinal cord compression. Systemic ALK-targeted therapy can be initiated subsequently, but urgent intervention to prevent skeletal complications should not be delayed by systemic treatment considerations.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1bef3b99e7ad",
    "question": "For a patient with Stage IIIC (T3, N3) non-small cell lung cancer confirmed by pathological examination, who has a resectable locoregional recurrence but also reduced pulmonary function on preoperative PFTs, is surgery still the preferred local treatment option compared to external-beam radiotherapy or SABR?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "In patients with resectable locoregional recurrence of Stage IIIC NSCLC, surgery is generally preferred. However, significantly reduced pulmonary function on preoperative PFTs may contraindicate surgery due to heightened perioperative risk. In such cases, external-beam radiotherapy or SABR becomes the more appropriate local therapy choice.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_424276e98b5c",
    "question": "For a patient with completely resected stage II non-small cell lung cancer who has completed adjuvant chemotherapy and shows no evidence of disease on imaging, is routine use of FDG-PET/CT recommended during follow-up surveillance for recurrence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "No, routine FDG-PET/CT is not recommended for surveillance in this scenario. Standard follow-up involves history and physical examination with chest CT at defined intervals, while FDG-PET/CT should be reserved for evaluating suspected recurrence or specific findings, not as part of routine monitoring.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e232f491da85",
    "question": "In a patient with newly diagnosed stage IVA, metastatic (M1b) non-squamous non-small cell lung cancer whose tumor tests negative for actionable molecular biomarkers and has a PD-L1 expression less than 1%, can initial systemic immunotherapy monotherapy with a PD-1/PD-L1 inhibitor alone be considered adequate, or is platinum-based chemotherapy a necessary component of first-line treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above",
            "PD-L1 <1%",
            "INITIAL SYSTEMIC THERAPY",
            "PS 0–2",
            "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
            "Tumor response evaluation",
            "Progression",
            "PS 0–2",
            "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
            "Systemic therapy, Progression (NSCL-K 4 of 5)"
          ]
        }
      }
    ],
    "answer": "When actionable molecular alterations are absent and PD-L1 expression is below 1% in advanced non-squamous NSCLC, initial systemic therapy should include platinum-based chemotherapy, rather than immunotherapy monotherapy; immunotherapy alone is not considered adequate due to poor efficacy in this biomarker-defined subgroup.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c3dc09fb64b9",
    "question": "In a patient diagnosed with stage IIIB non-small cell lung cancer (defined as T1–2, N3) who has not yet undergone pathologic confirmation of N3 disease, is it acceptable to proceed directly to systemic therapy without invasive nodal biopsy such as mediastinoscopy, EBUS, or needle biopsy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, systemic therapy initiation for stage IIIB non-small cell lung cancer is contingent upon pathologic confirmation of N3 disease using invasive modalities like mediastinoscopy, EBUS, or needle biopsy. Imaging alone is insufficient; pathologic verification of mediastinal or supraclavicular nodal involvement is a mandatory prerequisite for this treatment decision.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_405ab28a6fb4",
    "question": "In a patient with Stage II non-small cell lung cancer who underwent definitive radiotherapy as primary treatment, is routine use of FDG-PET/CT and brain MRI with contrast indicated during scheduled surveillance imaging when there is no evidence of clinical or radiographic disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
            "R2; Resection + systemic therapy or Concurrent chemoradiation",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, for Stage II non-small cell lung cancer patients treated with definitive radiotherapy and without clinical or radiographic evidence of disease, routine surveillance does not include FDG-PET/CT or brain MRI with contrast; scheduled follow-up consists of physical examination and chest CT at defined intervals.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_5a5e2eb51512",
    "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete resection (R0) and received no adjuvant chemotherapy or radiotherapy, is routine brain MRI indicated during scheduled surveillance if the patient is asymptomatic?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIA (T2b, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, routine brain MRI is not indicated for surveillance in asymptomatic patients with stage IIA (T2b, N0) non-small cell lung cancer who had complete resection without adjuvant therapy. Surveillance should rely on history, physical examination, and chest CT; brain MRI is reserved for evaluations triggered by symptoms or suspected recurrence.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_d24949f4b5cb",
    "question": "For a patient with stage IVA non-small cell lung cancer (NSCLC) presenting with a malignant pleural effusion and confirmed KRAS G12C mutation in a squamous cell carcinoma subtype, is the recommendation to perform broad molecular profiling—including EGFR, ALK, and other driver mutations—still applicable, or does squamous histology generally exclude the need for such molecular testing?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1a: pleural or pericardial effusion",
            "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
            "Positive",
            "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "KRAS G12C mutation positive"
          ]
        }
      }
    ],
    "answer": "Broad molecular profiling, including testing for EGFR, ALK, and other actionable mutations, is now recommended even for patients with squamous cell carcinoma if sufficient tissue is available, particularly in advanced-stage disease. Squamous histology no longer categorically excludes the need for comprehensive molecular testing, as actionable mutations can occasionally be present.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e29196cd89df",
    "question": "In a patient with newly diagnosed stage II non-small cell lung cancer (clinical T2b, N0) who also presents with moderate chronic obstructive pulmonary disease and decreased pulmonary function on preoperative testing, is definitive surgical resection still appropriate as the first-line treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "For stage II non-small cell lung cancer, definitive surgical resection is generally the preferred first-line treatment. However, in patients with moderate chronic obstructive pulmonary disease and reduced pulmonary function, surgical risk is significantly increased. In such scenarios, surgery may not be appropriate, and non-surgical options like definitive radiotherapy or chemoradiotherapy should be considered instead.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_4472a8281267",
    "question": "In a patient with invasive, non-metastatic breast cancer of pure mucinous histology, tumor size 0.9 cm (pT1), ER-positive, HER2-negative, and axillary node status pN0, is adjuvant endocrine therapy indicated even if the histology is considered favorable and the tumor is less than 1 cm?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
            "ER-positive and/or PR-positive or ER-negative and PR-negative",
            "Favorable Histologies (BINV-11)",
            "Pure tubular • Pure mucinous • Pure cribriform",
            "ER-positive and/or PR-positive, HER2-negative",
            "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
            "<1 cm",
            "Consider adjuvant endocrine therapy for risk reduction",
            "Follow-Up (BINV-17)"
          ]
        }
      }
    ],
    "answer": "Yes; despite favorable histology and small tumor size (<1 cm), consideration of adjuvant endocrine therapy for risk reduction is appropriate in ER-positive, HER2-negative cases, as per current treatment standards for localized breast cancer.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1760b11f0d54",
    "question": "In a patient diagnosed with non-small cell lung cancer, presenting with stage IVA (N0, M1a) characterized by a single contralateral lung nodule, is it appropriate to manage this case as two primary lung cancers instead of metastatic disease if both lesions are independently deemed curable?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treatment",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
          ]
        }
      }
    ],
    "answer": "Yes, when a patient with stage IVA (N0, M1a) non-small cell lung cancer presents with a solitary contralateral lung nodule and both lesions are considered independently resectable and curable, it is appropriate to treat them as two primary tumors rather than metastatic disease, potentially offering curative treatment for both.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c16dbdabfb89",
    "question": "In a patient with localized, non-inflammatory, non-metastatic invasive breast cancer (clinical stages T1–T4, N0, M0) who is HER2-positive and ER/PR-positive, if axillary staging reveals at least one ipsilateral lymph node metastasis >2 mm (pN+), is adjuvant chemotherapy with both trastuzumab and pertuzumab plus endocrine therapy appropriate, or should adjuvant chemotherapy with trastuzumab plus endocrine therapy alone be prioritized?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
            "ER-positive and/or PR-positive",
            "HER2-positive",
            "BINV-5",
            "Ductal/NST • Lobular • Mixed • Micropapillary",
            "pN+ (≥1 ipsilateral metastases >2 mm)",
            "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred) and endocrine therapy",
            "Follow-Up (BINV-17)"
          ]
        }
      }
    ],
    "answer": "For HER2-positive, ER/PR-positive breast cancer with pN+ (≥1 ipsilateral node metastasis >2 mm), adjuvant chemotherapy combined with trastuzumab and pertuzumab plus endocrine therapy is preferred over chemotherapy with trastuzumab plus endocrine therapy, as dual HER2 blockade improves disease-free survival in this higher-risk subgroup.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_404e7326dffa",
    "question": "In cases of multiple lung cancers (suspected or confirmed) classified as N0–1, where a dominant nodule shows evidence of growth and definitive local therapy is not possible, does the selection of palliative chemotherapy inherently assume the presence of symptomatic disease, or can it also be considered for asymptomatic patients?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Multiple lung cancers (suspected or confirmed) (N0–1)",
            "Multidisciplinary evaluation",
            "Dominant nodule with evidence of growth",
            "Definitive local therapy not possible",
            "Palliative chemotherapy ± local palliative therapy or Observe",
            "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
            "Locoregional recurrence or symptomatic local disease",
            "Severe hemoptysis",
            "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Palliative chemotherapy may be considered regardless of symptom presence in this scenario. While symptomatic disease often prompts intervention, the recommendation does not strictly require symptoms, and palliative chemotherapy can be appropriate for both symptomatic and asymptomatic patients when definitive local therapy is unfeasible.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_5ad29fc270e6",
    "question": "In a patient with newly diagnosed stage II non–small cell lung cancer (T1abc–T2ab, N1 or T2b, N0), who also has significant renal dysfunction precluding contrast-enhanced imaging, is it still justified to perform a brain MRI as part of initial staging?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Yes. Brain MRI with contrast is routinely indicated in stage II non–small cell lung cancer for initial staging, as intracranial metastases may alter management; if contrast is contraindicated due to renal dysfunction, non-contrast brain MRI or alternative brain imaging should still be considered to adequately assess for brain metastasis.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ee086280b61a",
    "question": "In a patient diagnosed with squamous cell non-small cell lung cancer who has a confirmed KRAS G12C mutation and has previously received radiotherapy, is broad molecular profiling including EGFR, ALK, ROS1, and additional driver mutations still recommended as a standard step before initiating systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "KRAS G12C mutation positive"
          ]
        }
      }
    ],
    "answer": "Yes, broad molecular profiling is recommended even in squamous cell carcinoma with a known KRAS G12C mutation and prior radiotherapy. Comprehensive testing, including driver mutations such as EGFR, ALK, ROS1, and others, is essential to rule out actionable alterations, as rare molecular targets may also be present in squamous histology and impact systemic therapy selection.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_126a8c0c6ce0",
    "question": "In a patient with stage IIB non-small cell lung cancer (T3, N0) who has undergone surgical resection but is found to have positive microscopic margins (R1), does the recommendation for resection followed by systemic therapy or chemoradiation implicitly assume there is no evidence of distant metastatic disease at the time of postoperative evaluation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
            "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Severe hemoptysis",
            "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Yes, the recommendation for resection plus systemic therapy or chemoradiation after R1 resection in stage IIB (T3, N0) non-small cell lung cancer presumes that there is no clinical or radiographic evidence of distant metastatic disease, as the treatment intent remains locoregional control.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_28f38c0f5425",
    "question": "In a patient with operable, invasive, non-metastatic breast cancer (M0), who has a clinically negative axilla (cN0) on examination and imaging, but presents with two sentinel lymph nodes positive after undergoing breast-conserving surgery, can omission of axillary lymph node dissection (ALND) still be considered appropriate if the patient has received preoperative systemic (neoadjuvant) therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS not possible",
            "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
            "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
            "SLN mapping and excision",
            "SLN positive",
            "Breast-conserving surgery",
            "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
            "No",
            "ALND level I/II"
          ]
        }
      }
    ],
    "answer": "Omission of axillary lymph node dissection (ALND) is not considered appropriate in this scenario, as the eligibility for skipping ALND after finding 1–2 positive sentinel lymph nodes applies only to patients who have not received preoperative systemic therapy. Preoperative (neoadjuvant) therapy alters nodal evaluation and exclusion criteria for ALND omission.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_26a7ad9cab41",
    "question": "For a patient with stage IA (T1a, N0) non-small cell lung cancer (NSCLC) who has undergone resection but is found to have positive surgical margins (R1 or R2), is adjuvant radiotherapy routinely indicated, or is re-resection preferred as the primary management strategy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "For stage IA (T1a, N0) NSCLC with positive margins after surgery, re-resection is the preferred primary management; adjuvant radiotherapy is a category 2B alternative but not routinely indicated. Definitive radiotherapy may be considered only if re-resection is not feasible.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3c79c3124da2",
    "question": "For a patient with completely resected stage IA non-small cell lung cancer (T1abc, N0), who has positive surgical margins (R1 or R2), is resection always preferred over radiotherapy, or are there clinical circumstances where radiotherapy may be considered appropriate as a primary approach?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Severe hemoptysis",
            "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "In completely resected stage IA non-small cell lung cancer with positive margins, re-resection is the preferred option if technically feasible and medically suitable. However, radiotherapy is considered a category 2B alternative when re-resection is not feasible due to patient comorbidities, anatomical limitations, or surgical risk, making it an acceptable primary local treatment in select circumstances.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1cce9f1c3fe5",
    "question": "In a patient with stage IV, M1b non-small cell lung cancer who has limited distant metastases and a performance status of 3–4, is systemic therapy the recommended approach even in the presence of significant comorbidities such as severe cardiac dysfunction?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Limited metastases",
            "Stage IV, M1b (NSCL-15)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "PS 3–4",
            "Systemic Therapy for Metastatic Disease (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, systemic therapy is generally not recommended for patients with stage IV, M1b non-small cell lung cancer who have a performance status of 3–4 and significant comorbidities like severe cardiac dysfunction, as the risks and poor tolerance typically outweigh potential benefits in this setting.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ab2d684f3f14",
    "question": "For a patient with stage III non-small cell lung cancer (NSCLC) who received definitive radiotherapy as the primary treatment and now demonstrates no evidence of clinical or radiographic disease, should routine follow-up imaging protocols include FDG-PET/CT scans, or is chest CT with or without contrast sufficient for surveillance in the absence of new symptoms or findings?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Routine follow-up imaging for stage III NSCLC post-definitive radiotherapy without evidence of disease should utilize chest CT with or without contrast, as FDG-PET/CT is not routinely indicated in asymptomatic patients during surveillance. FDG-PET/CT is reserved for patients with recurrence or new symptoms suggestive of disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_22b34b1ece73",
    "question": "For a patient with non-small cell lung cancer, T3 tumor invading the chest wall, and single brain metastasis, should priority be given to systemic therapy or local treatment (such as surgery or radiotherapy) for the thoracic lesion?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "In cases of non-small cell lung cancer with a T3 chest wall-invading tumor and limited brain metastasis (oligometastatic disease), priority is generally given to systemic therapy as initial treatment, followed by consideration of local therapies for both primary and metastatic sites if good functional status and response are achieved. Local treatment alone is not standard in the presence of distant metastasis.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f677d6988fcb",
    "question": "For a patient with stage IIIC (T3, N3) non-small cell lung cancer who also presents with a separate pulmonary nodule in the contralateral lung, should management be aligned with limited stage disease protocols or primarily follow the approach for metastatic (stage IV) disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Presence of a separate pulmonary nodule in the contralateral lung is classified as stage IV disease, indicating metastatic involvement. In this situation, management should primarily follow treatment protocols for metastatic (stage IV) non-small cell lung cancer rather than limited stage (stage IIIC) protocols.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_d167777f40cb",
    "question": "For a patient with localized, operable, non-inflammatory, non-metastatic (M0) breast cancer that is HR-positive and HER2-positive, if the pathological complete response (pCR, ypT0N0) is achieved after preoperative systemic therapy, is adjuvant HER2-directed therapy with trastuzumab ± pertuzumab still indicated regardless of initial nodal status?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS possible",
            "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
            "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
            "HR-positive/ HER2-positive",
            "ypT0N0 or pCR",
            "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
          ]
        }
      }
    ],
    "answer": "Yes, adjuvant HER2-directed therapy with trastuzumab is indicated for all HR-positive/HER2-positive patients achieving pCR after preoperative systemic therapy, with the addition of pertuzumab for initially node-positive cases; the need for HER2-targeted therapy does not depend on achievement of pCR alone.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e623c4100f53",
    "question": "For a patient with completely resected stage IIA (T2b, N0) non–small cell lung cancer and negative surgical margins (R0), is routine surveillance with FDG-PET/CT or brain MRI indicated in the absence of symptoms or abnormal findings on chest CT?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIA (T2b, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "No, in completely resected stage IIA (T2b, N0) non–small cell lung cancer with negative margins, routine surveillance with FDG-PET/CT or brain MRI is not indicated if there are no symptoms or abnormal imaging findings; standard surveillance should include history, physical examination, and periodic chest CT only.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c295418e017c",
    "question": "In a patient with stage IIIB non-small cell lung cancer (T1–2, N3), if the diagnosis of N3 lymph node involvement is based solely on radiological findings without pathologic confirmation, is this sufficient to initiate definitive stage IIIB treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "PS 0–2",
            "Limited progression confirmed",
            "Other site",
            "Treatment of Thoracic Disease (NSCL-16)"
          ]
        }
      }
    ],
    "answer": "No; initiation of definitive treatment for stage IIIB non-small cell lung cancer requires pathologic confirmation of N3 lymph node involvement. Radiological findings alone are insufficient, as pathological assessment (e.g., mediastinoscopy, EBUS, needle biopsy) is essential to establish N3 disease before proceeding with stage-specific therapy.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b8460b2d62bc",
    "question": "In a patient with advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology, whose tumor harbors an ALK rearrangement identified via molecular testing prior to any systemic therapy, and who concurrently has significant hepatic impairment, is first-line use of ceritinib still an appropriate choice?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "ALK rearrangement positive",
            "ALK rearrangement",
            "ALK rearrangement discovered prior to first-line systemic therapy",
            "Other Recommended Ceritinibr (category 1)",
            "Progression",
            "Subsequent Therapy (NSCL-28)"
          ]
        }
      }
    ],
    "answer": "Ceritinib, while a recommended first-line therapy for ALK-rearranged advanced NSCLC, is associated with a risk of hepatotoxicity and requires dose adjustment or may be contraindicated in patients with significant hepatic impairment. In such cases, alternative ALK inhibitors with more favorable hepatic safety profiles, such as alectinib, should be prioritized.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_48f6c91d41be",
    "question": "For a patient with completely resected stage IIB non-small cell lung cancer who underwent surgery followed by adjuvant chemotherapy, is routine FDG-PET/CT or brain MRI indicated during scheduled surveillance in the absence of symptoms or suspicious findings on chest CT?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
            "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "No, for patients with stage IIB non-small cell lung cancer treated with surgery and adjuvant chemotherapy, routine FDG-PET/CT or brain MRI is not indicated during surveillance if there are no symptoms or radiographic suspicion on chest CT; surveillance should be performed with history, physical examination, and chest CT.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_735b711ec4d7",
    "question": "In a patient with newly diagnosed stage IVA (M1b) non-small cell lung cancer (adenocarcinoma subtype) and confirmed ALK rearrangement, if the brain MRI shows asymptomatic small brain metastasis but no neurological symptoms, should alectinib or crizotinib be prioritized as first-line therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "ALK rearrangement positive",
            "ALK rearrangement",
            "ALK rearrangement discovered during first-line systemic therapy",
            "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
            "Progression",
            "Subsequent Therapy (NSCL-28)"
          ]
        }
      }
    ],
    "answer": "Alectinib should be prioritized over crizotinib as first-line therapy for advanced ALK-rearranged non-small cell lung cancer, especially in the presence of brain metastases, due to superior central nervous system efficacy and overall survival benefit demonstrated in clinical trials.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_7a37422074e0",
    "question": "For a patient with newly diagnosed stage IIIB (T1–2, N3) non-small cell lung cancer and confirmed squamous cell carcinoma histology, is broad molecular profiling including EGFR, ALK, ROS1, and other driver mutations routinely required even in the absence of non-squamous features?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "For confirmed squamous cell carcinoma, broad molecular profiling—including EGFR, ALK, and ROS1 testing—is not routinely required unless there are non-squamous components, young age, or minimal smoking history. In pure squamous cell carcinoma of standard risk factors, routine molecular testing is not indicated.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2e2b5786e4c4",
    "question": "For a patient with advanced nonsquamous non-small cell lung cancer showing bone metastases and an identified elevated risk of fracture, is it appropriate to proceed directly with systemic therapy without first considering orthopedic stabilization and palliative radiotherapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Bone metastases",
            "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above"
          ]
        }
      }
    ],
    "answer": "No, for advanced nonsquamous NSCLC with bone metastases and a high fracture risk, orthopedic stabilization and palliative external-beam radiotherapy should be prioritized before systemic therapy to prevent pathological fracture and associated morbidity.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_89f8dd077ced",
    "question": "In a patient with stage IIIB non-small cell lung cancer (T3, N2) who achieved R0 resection after concurrent chemoradiation and now has no clinical or radiographic evidence of disease at follow-up, is FDG-PET/CT routinely indicated as part of surveillance imaging in the absence of suspicious symptoms or abnormal findings?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
            "R2; Concurrent chemoradiation",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, FDG-PET/CT is not routinely indicated for surveillance in patients with no evidence of disease after definitive treatment for stage IIIB non-small cell lung cancer. Standard follow-up includes history and physical examination and chest CT at prescribed intervals, with FDG-PET/CT reserved for suspicious new or ambiguous findings.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f3cf320713a4",
    "question": "In a patient with advanced squamous cell carcinoma of the lung and confirmed RET rearrangement, is RET-targeted therapy a valid first-line systemic treatment option, or should standard chemotherapy or immunotherapy be preferred given the histologic subtype?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "RET rearrangement positive"
          ]
        }
      }
    ],
    "answer": "For advanced squamous cell carcinoma of the lung with RET rearrangement, RET-targeted therapy is not currently standard first-line treatment due to limited supporting data in squamous histology. Standard platinum-based chemotherapy, with or without immunotherapy based on PD-L1 status, remains the recommended initial approach, reserving RET inhibitors primarily for non-squamous subtypes.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_62464228095b",
    "question": "In a patient with localized, invasive, non-inflammatory, non-metastatic (M0) breast cancer who had a primary tumor larger than 5 cm, negative axillary lymph nodes, and underwent total mastectomy with surgical axillary staging, is chest wall radiotherapy still indicated if the patient did not receive preoperative systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "Negative axillary nodes and tumor >5 cm",
            "Consider RT to chest wall ± comprehensive RNI (including any portion of the undissected axilla at risk)."
          ]
        }
      }
    ],
    "answer": "Yes, postmastectomy radiotherapy to the chest wall—with or without comprehensive regional nodal irradiation—is recommended for patients with negative axillary nodes and a tumor size greater than 5 cm, regardless of whether preoperative systemic therapy was administered.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e2a555d8069d",
    "question": "In a patient with stage IV, M1b advanced non-small cell lung cancer (adenocarcinoma histology) who is confirmed to have a MET exon 14 skipping mutation prior to any first-line systemic therapy, is the use of capmatinib or tepotinib as first-line treatment predicated on the presence or absence of brain metastases?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "METex14 skipping mutation positive",
            "METex14 skipping mutation",
            "METex14 skipping mutation discovered prior to first-line systemic therapy",
            "Preferred: Capmatinib or Tepotinib",
            "Progression",
            "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
          ]
        }
      }
    ],
    "answer": "The selection of capmatinib or tepotinib as first-line therapy for advanced NSCLC with MET exon 14 skipping mutation does not depend on the presence or absence of brain metastases; both agents are recommended for all eligible patients regardless of central nervous system involvement.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b881f0b00752",
    "question": "In a patient diagnosed with stage IVA non-small cell lung cancer presenting with malignant pleural effusion, whose tumor is squamous cell carcinoma, broad molecular testing including EGFR, ALK, KRAS, and other actionable mutations yields negative results, and PD-L1 expression is below 1%. Is immunotherapy with a PD-1/PD-L1 inhibitor as monotherapy considered appropriate first-line systemic treatment in this setting?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1a: pleural or pericardial effusion",
            "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
            "Positive",
            "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above"
          ]
        }
      }
    ],
    "answer": "No, in patients with squamous cell carcinoma of the lung, stage IV disease, negative for actionable molecular alterations and with PD-L1 expression less than 1%, first-line monotherapy with a PD-1/PD-L1 inhibitor is not indicated. Standard care favors platinum-based doublet chemotherapy; immunotherapy may be added in combination but not as monotherapy in this scenario.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e7e1a5cbdc36",
    "question": "In a patient diagnosed with breast ductal carcinoma in situ (DCIS) concomitant with Paget disease of the nipple-areola complex (NAC), if imaging and clinical examination do not identify an underlying invasive breast lesion, is systemic adjuvant therapy routinely indicated?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Clinical suspicion of Paget disease",
            "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
            "Examination and imaging negative for breast lesion",
            "Examination or imaging positive for breast lesion",
            "Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC",
            "Breast DCIS and NAC Paget",
            "See NCCN Guidelines for Noninvasive Breast Cancer for DCIS (DCIS-1)",
            "Appropriate systemic adjuvant therapy as clinically indicated, See NCCN Guidelines for DCIS or Invasive Breast Cancer"
          ]
        }
      }
    ],
    "answer": "Systemic adjuvant therapy is not routinely indicated for pure DCIS with associated Paget disease of the NAC in the absence of invasive carcinoma, as current evidence supports local therapy alone unless additional high-risk features or invasive disease are present.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_36aefb952d97",
    "question": "In a patient with advanced squamous cell carcinoma of the lung who is found to harbor an EGFR exon 20 insertion mutation, is the use of amivantamab-vmjw as systemic therapy predicated upon the completion of broad molecular profiling for other actionable genetic alterations?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "EGFR exon 20 insertion mutation positive",
            "EGFR exon 20 insertion mutation",
            "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
            "Tumor response evaluation",
            "Progression",
            "Amivantamab-vmjw",
            "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
          ]
        }
      }
    ],
    "answer": "The use of amivantamab-vmjw specifically targets tumors with EGFR exon 20 insertion mutations and is not contingent on identification of other actionable mutations. However, comprehensive molecular profiling is recommended to exclude the presence of additional targetable alterations, which may influence therapy selection.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2158fe43c68b",
    "question": "In a patient with non-small cell lung cancer presenting with T4 tumor extension involving resectable invasion of the mediastinum (N0–1 disease), is concurrent chemoradiation still recommended if the patient has severely impaired pulmonary function tests (PFTs) not amenable to improvement?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Trachea/carina or mediastinum",
            "Treatment (NSCL-7)",
            "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
            "Systemic therapy or Concurrent chemoradiation",
            "Surgical reevaluation including chest CT ± PET/CT",
            "Surgery",
            "Margins positive (R1, R2)",
            "Resection and/or RT boost",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "Concurrent chemoradiation is generally contraindicated in patients with severely impaired pulmonary function because of the high risk of treatment-related morbidity and mortality. For such patients, alternative approaches such as systemic therapy alone or individualized, less intensive regimens should be considered.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ef60e593c48b",
    "question": "For a patient with stage IIIA (T1–2, N2) non-small cell lung cancer who underwent definitive chemoradiation and currently has no clinical or radiographic evidence of disease, is brain MRI with contrast indicated as part of routine surveillance in the absence of neurological symptoms?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
            "R2; Concurrent chemoradiation",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, routine brain MRI with contrast is not indicated for surveillance in asymptomatic patients with stage IIIA non-small cell lung cancer post-definitive chemoradiation and no evidence of disease. Imaging of the brain is reserved for cases with neurological symptoms or clinical suspicion of recurrence.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_052f12eb0949",
    "question": "In a patient with non-small cell lung cancer staged as IIIB (T2, N3), if mediastinal N3 lymph node status has not yet been pathologically confirmed but imaging studies including FDG-PET/CT and brain MRI suggest N3 disease, is it appropriate to proceed directly to treatment for stage IIIB disease, or is pathological confirmation of N3 disease a necessary prerequisite before initiation of definitive treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "N3 nodes positive, M0",
            "Stage IIIB or Stage IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
          ]
        }
      }
    ],
    "answer": "Pathological confirmation of N3 lymph node involvement is a necessary prerequisite before initiating definitive treatment for stage IIIB (T2, N3) non-small cell lung cancer. Imaging studies alone are insufficient to establish the diagnosis, as invasive biopsy methods such as mediastinoscopy or EBUS are required to confirm N3 status for accurate staging and appropriate therapeutic planning.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9ea06e2cdb5b",
    "question": "In a patient with stage IVA non-small cell lung cancer presenting with malignant pleural effusion and confirmed ERBB2 (HER2) mutation, is local therapy such as pleurodesis sufficient as the sole treatment, or is it necessary to initiate systemic therapy targeting stage IV disease concurrently?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1a: pleural or pericardial effusion",
            "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
            "Positive",
            "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "ERBB2 (HER2) mutation positive"
          ]
        }
      }
    ],
    "answer": "Local therapy such as pleurodesis addresses symptoms from pleural effusion but is not sufficient as the sole treatment for stage IVA disease. Systemic therapy targeting stage IV non-small cell lung cancer, guided by molecular findings such as ERBB2 (HER2) mutation, is necessary and should be initiated concurrently with any local measures.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f70290dee120",
    "question": "For a patient with Stage IA (T1abc, N0) non–small cell lung cancer who has positive surgical margins (R1 or R2), is it appropriate to proceed with radiotherapy as definitive local treatment if the patient is not a candidate for re-resection?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes; for Stage IA (T1abc, N0) non–small cell lung cancer patients with positive margins (R1 or R2) who cannot undergo further surgical resection, radiotherapy is an accepted alternative local treatment, although it is considered a category 2B recommendation and may have less robust supporting evidence compared to re-resection.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_dc009e6f6462",
    "question": "In a patient with newly diagnosed non-small cell lung cancer presenting with multiple pulmonary lesions and an ECOG performance status of 2, but without previously documented biomarker testing, is it appropriate to initiate systemic therapy for metastatic disease without waiting for molecular results?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "PS 0–2",
            "Multiple lesions",
            "Systemic Therapy for Metastatic Disease (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Systemic therapy for metastatic non-small cell lung cancer can be initiated in patients with multiple lesions and ECOG PS 0–2; however, current clinical practice requires biomarker testing prior to systemic treatment selection. Empiric therapy may occasionally proceed if rapid symptom control is necessary, but targeted or immunotherapy regimens should await molecular results whenever feasible.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_714b2e836488",
    "question": "In a patient with newly diagnosed stage IIIA non-small cell lung cancer (T1–2, N3), if mediastinal N3 involvement is confirmed only by FDG-PET/CT without pathologic verification via biopsy or mediastinoscopy, is it clinically justified to proceed directly to systemic therapy for metastatic disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, reliance solely on FDG-PET/CT for N3 mediastinal node involvement is insufficient to define metastatic disease; pathologic confirmation through biopsy or mediastinoscopy is required before systemic therapy is initiated, as imaging alone may produce false positives.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9781276a4168",
    "question": "A patient with invasive, non-inflammatory, non-metastatic breast cancer is clinically staged as cT1c, cN0, and has HER2-positive disease. Is preoperative systemic therapy a justified approach in this case, or is it recommended only for cT2 or node-positive tumors?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS not possible",
            "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
            "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
            "HR-positive/ HER2-negative",
            "ypT0N0 or pCR",
            "Adjuvant endocrine therapy (category 1)"
          ]
        }
      }
    ],
    "answer": "Preoperative systemic therapy is justified for cT1c, cN0, HER2-positive breast cancer. Its indication is not confined to cT2 or node-positive cases; HER2-positive status in cT1c tumors serves as an independent criterion warranting neoadjuvant systemic treatment.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1e5c98a41a08",
    "question": "For a patient with non–small cell lung cancer presenting with stage IIIC disease (T3, N3, M0) and confirmed mediastinal lymph node involvement via EBUS biopsy, does the selection of perioperative therapy implicitly require the absence of distant metastases on brain MRI and FDG-PET/CT imaging?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "N3 nodes positive, M0",
            "Stage IIIB or Stage IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "PS 0–2",
            "Limited progression confirmed",
            "Brain",
            "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
            "Treatment of Thoracic Disease (NSCL-16)"
          ]
        }
      }
    ],
    "answer": "Yes. The use of perioperative therapy in stage IIIC (T3, N3, M0) non–small cell lung cancer is contingent on confirming M0 status, which by definition excludes distant metastases. Negative findings on brain MRI and FDG-PET/CT are necessary prerequisites before considering perioperative interventions in this population.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_77a103e7ef24",
    "question": "In a postmenopausal woman with ER-positive, HER2-negative, stage IV (M1) breast cancer without bone or visceral crisis, who has progressed on first-line endocrine therapy within one year, is immediate initiation of additional cytotoxic chemotherapy required, or is continuation of alternative lines of endocrine therapy still preferred until visceral crisis or unacceptable toxicity develops?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Metastatic (M1) invasive breast cancer",
            "Stage IV (M1) or Recurrent disease",
            "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
            "Stage IV (M1) or Recurrent",
            "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
            "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
            "Recurrent unresectable (local or regional) or stage IV (M1) disease",
            "Bone disease not present",
            "ER- and/or PR-positive; HER2-negative",
            "BINV-22",
            "No visceral crisis and Prior endocrine therapy within 1 y",
            "Postmenopausal",
            "Systemic therapy",
            "Continue endocrine therapy until progression or unacceptable toxicity",
            "Progression",
            "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
            "Alternate systemic therapy",
            "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
            "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
          ]
        }
      }
    ],
    "answer": "Continuation of alternative lines of endocrine therapy remains preferred until the onset of visceral crisis or unacceptable toxicity. Immediate initiation of additional cytotoxic chemotherapy is not required in the absence of visceral crisis, as sequential endocrine therapies should be exhausted first in ER-positive, HER2-negative, postmenopausal metastatic breast cancer.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_a5b9519c3973",
    "question": "In a patient with stage IA (T1aN0) non-small cell lung cancer who has undergone surgical resection but has positive margins (R1), is definitive radiation therapy always required, or does re-resection remain the preferred option when feasible?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "For stage IA (T1aN0) non-small cell lung cancer with positive resection margins (R1), repeat surgical resection is preferred when feasible. Definitive radiation therapy is considered a secondary (category 2B) option if re-resection is not possible. Therefore, re-resection takes priority over radiation in the absence of surgical contraindications.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f7826fe22b55",
    "question": "For a patient with stage I non-small cell lung cancer who underwent surgery with positive margins (R1/R2), if the patient has significant renal impairment precluding the use of contrast agents, is routine post-treatment surveillance with non–contrast-enhanced chest CT still appropriate for early detection of recurrence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (T2a, N0); Margins positive (R1, R2)",
            "Resection (preferred) ± systemic therapy or RT",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, non–contrast-enhanced chest CT remains appropriate for surveillance in stage I NSCLC patients after surgery, even with positive margins and renal impairment, as contrast enhancement is not mandatory for routine follow-up and does not compromise the ability to detect early recurrence.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9bbd3f608c64",
    "question": "In a patient with resectable non-small cell lung cancer staged as T2N2M0, who has undergone FDG-PET/CT and brain MRI showing no distant metastases, does initiation of systemic therapy without prior mediastinal lymph node biopsy assume that radiographic findings alone are sufficient for N2 confirmation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "N1 or N2 nodes positive, M0",
            "Treatment (NSCL-10)",
            "Mediastinal Biopsy Findings",
            "T1–3, N2 nodes positive, M0",
            "Systemic therapy ± RT",
            "No apparent progression",
            "Consider RT",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "No, initiation of systemic therapy in T2N2M0 non-small cell lung cancer generally requires pathologic confirmation of mediastinal (N2) lymph node involvement; radiographic evidence alone is typically insufficient, as accurate staging impacts treatment selection and prognosis.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_66707aee03da",
    "question": "In a patient with stage IIIB (T3, N2) non-small cell lung cancer presenting with symptomatic superior vena cava (SVC) obstruction, but who has previously received concurrent chemoradiation, is placement of an SVC stent still an appropriate management option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Yes, for a patient with SVC obstruction and a history of prior concurrent chemoradiation, placement of a superior vena cava stent remains an appropriate management to promptly relieve obstructive symptoms, regardless of previous chemoradiation.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9c500821ed6e",
    "question": "For a patient with stage IA peripheral non-small cell lung cancer (T1a-c, N0), if pulmonary function tests have not yet been completed, should surgical resection proceed before obtaining these results, or is preoperative pulmonary function assessment mandatory to determine operability?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Distant metastases",
            "Limited metastases",
            "Stage IV, M1b (NSCL-15)"
          ]
        }
      }
    ],
    "answer": "Preoperative pulmonary function assessment is mandatory in stage IA peripheral non-small cell lung cancer if not previously performed. Proceeding to surgical resection without prior evaluation of pulmonary reserve is not appropriate, as operability and perioperative risk must be reliably assessed before surgery is undertaken.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_62e2a2fdb703",
    "question": "In a patient with stage IIIB squamous cell carcinoma of the lung and biopsy-confirmed N2 mediastinal lymph node involvement, is broad molecular profiling for EGFR, ALK, ROS1, and other mutations still recommended, or is such molecular testing primarily reserved for nonsquamous histologies?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
            "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Broad molecular profiling, including EGFR, ALK, ROS1, and other driver mutations, is primarily emphasized for nonsquamous NSCLC; however, it should still be considered for squamous cell carcinoma, especially in never-smokers or younger patients, as actionable mutations can occasionally be present.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_6d23c501b5b5",
    "question": "In a patient with a stage IIB non-small cell lung cancer (T3, N0), who is found to have a separate pulmonary nodule in the same lobe as the primary tumor, does this presentation remain classified as stage IIB, or does the presence of the additional nodule change the staging to a more advanced group?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
          ]
        }
      }
    ],
    "answer": "The presence of a separate pulmonary nodule in the same lobe as the primary tumor in non-small cell lung cancer upstages the tumor to T3; if nodal status remains N0–1, this is still classified as stage IIB or IIIA depending on N status. Thus, the additional nodule in the same lobe does not automatically shift classification outside the IIB or IIIA categories but indicates a higher T descriptor within these stages.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_a4cf950a5a2b",
    "question": "For a patient with completely resected Stage IIB (T3, N0) non-small cell lung cancer who has negative surgical margins and no evidence of disease on post-operative imaging, is routine surveillance with brain MRI indicated during follow-up in the absence of neurological symptoms?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Routine surveillance with brain MRI is not indicated for asymptomatic patients with resected Stage IIB non-small cell lung cancer and no evidence of disease; brain MRI is reserved for evaluation upon recurrence or the development of neurological symptoms.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3ee9afb9d79f",
    "question": "In a patient with advanced non–small cell lung cancer (adenocarcinoma subtype) who is negative for all actionable molecular biomarkers and has a PD-L1 tumor proportion score less than 1%, but whose performance status deteriorates to ECOG 3, is initial systemic therapy still considered appropriate, or should best supportive care take precedence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above",
            "PD-L1 <1%",
            "INITIAL SYSTEMIC THERAPY",
            "PS 0–2",
            "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
            "Tumor response evaluation",
            "Progression",
            "PS 3–4",
            "Best supportive care NCCN Guidelines for Palliative Care"
          ]
        }
      }
    ],
    "answer": "For advanced non–small cell lung cancer patients with adenocarcinoma histology, no actionable molecular alterations, and PD-L1 <1%, initial systemic therapy is indicated only for those with ECOG performance status 0–2. If performance status is ECOG 3–4, systemic therapy is not recommended, and best supportive care becomes the primary approach.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_eaa8eeb2a3ab",
    "question": "For a patient with newly diagnosed stage IIIB (T3, N2) non-small cell lung cancer who presents with symptomatic superior vena cava (SVC) obstruction, and who has not previously received chemotherapy or radiation, is it appropriate to pursue concurrent chemoradiation rather than immediate SVC stent placement as the initial intervention?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "In the setting of symptomatic SVC obstruction due to stage IIIB (T3, N2) NSCLC, immediate SVC stent placement is prioritized to rapidly relieve symptoms. Concurrent chemoradiation can follow stenting but is not the initial intervention when urgent symptom relief is needed.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ac35e023f107",
    "question": "For a patient with resectable non-small cell lung cancer classified as stage IIIA (T4, N0–1), if intraoperative pathology reveals positive surgical margins (R1), is surgery alone an adequate definitive treatment in this context?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
            "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Contralateral mediastinal node negative",
            "Ipsilateral mediastinal node negative (T4, N0–1)",
            "Treatment for Stage IIIA (NSCL-7)",
            "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
            "Surgery (preferred)",
            "Margins positive",
            "R1",
            "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "No, surgery alone is insufficient when positive margins (R1) are detected in resectable stage IIIA (T4, N0–1) non-small cell lung cancer. Additional treatment with chemotherapy or chemoradiation is required post-resection to address microscopic residual disease and reduce recurrence risk.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f962dc515ac3",
    "question": "For a patient with stage IIB (T3, N0) non-small cell lung cancer who underwent surgical resection with positive margins (R2 resection), is it clinically appropriate to proceed directly to surveillance without additional systemic therapy or concurrent chemoradiation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
            "R2; Resection + systemic therapy or Concurrent chemoradiation",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, proceeding directly to surveillance is not clinically appropriate for stage IIB (T3, N0) non-small cell lung cancer with R2 resection. Incomplete resection (R2) requires additional systemic therapy and/or concurrent chemoradiation to address residual disease before initiating routine surveillance.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2215b19f0054",
    "question": "In a patient with advanced stage IVA (M1b) squamous cell carcinoma of the lung who harbors a BRAF V600E mutation, is administration of dabrafenib plus trametinib contingent upon the completion or interruption of the current first-line systemic therapy, or can it be initiated immediately upon discovery of the mutation regardless of ongoing treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "BRAF V600E mutation positive",
            "BRAF V600E MUTATION",
            "BRAF V600E mutation discovered during first-line systemic therapy",
            "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
            "Progression",
            "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
          ]
        }
      }
    ],
    "answer": "Initiation of dabrafenib plus trametinib in a patient with BRAF V600E-mutated advanced squamous cell lung carcinoma is recommended only after completion or interruption of the ongoing first-line systemic therapy; immediate switch is not supported if current treatment is still ongoing and effective.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_703f38103b40",
    "question": "In patients with stage I–II non-small cell lung cancer who have undergone primary treatment with surgery and adjuvant chemotherapy, is routine brain MRI indicated as part of scheduled surveillance imaging if there are no clinical symptoms suggestive of central nervous system involvement?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, routine brain MRI is not indicated for surveillance in asymptomatic stage I–II non-small cell lung cancer patients following surgery and adjuvant chemotherapy; brain MRI is reserved for evaluation of recurrence or when neurologic symptoms suggest possible brain metastases.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_36da367b6ae8",
    "question": "For a patient diagnosed with squamous cell carcinoma of the lung and confirmed stage IIIA disease (T4, N1) with no evidence of distant metastasis on FDG-PET/CT and brain MRI, is comprehensive molecular testing for EGFR, ALK, and other targetable mutations an essential prerequisite before initiating perioperative therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Comprehensive molecular testing is not considered an essential prerequisite for initiating perioperative therapy in stage IIIA squamous cell carcinoma of the lung, as actionable mutations are rare in this subtype and molecular profiling is recommended but not mandatory prior to surgery or chemoradiation.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_4e7853162f2a",
    "question": "For a patient with resectable stage IIIA (T1–2, N2) non-small cell lung cancer, if mediastinal lymph node involvement is confirmed pathologically but the patient has significant impairment on pulmonary function tests (PFTs), is perioperative therapy still considered appropriate?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Perioperative therapy in resectable stage IIIA (T1–2, N2) non-small cell lung cancer presupposes adequate pulmonary function to tolerate surgery. Significant impairment on PFTs generally contraindicates surgical intervention, making perioperative therapy inappropriate unless pulmonary function can be optimized.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_acb15f211161",
    "question": "In a patient with stage II non-small cell lung cancer who previously underwent primary surgery with negative margins but develops locoregional recurrence causing symptomatic superior vena cava (SVC) obstruction, is concurrent chemoradiation an appropriate initial management even if the patient previously did not receive chemoradiation during initial therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
            "R2; Resection + systemic therapy or Concurrent chemoradiation",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, for patients with locoregional recurrence and symptomatic SVC obstruction who did not receive prior chemoradiation, concurrent chemoradiation is an appropriate initial management. This approach targets both the local recurrence and relieves SVC obstruction, provided there is no prior definitive chemoradiation.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3d3d83c866ba",
    "question": "For a patient with non-small cell lung cancer who presents with separate pulmonary nodules located in the same lobe as the primary tumor (classified as T3, N0–1), is surgical resection still considered the primary treatment option if the patient has normal pulmonary function and no evidence of mediastinal lymph node involvement on FDG-PET/CT?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
            "Surgery after preoperative systemic therapy, if planned",
            "N2",
            "Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "Yes, surgical resection remains the mainstay treatment for non-small cell lung cancer with separate nodules in the same lobe (T3, N0–1) when pulmonary function is adequate and mediastinal lymph nodes are negative, as there is no indication for upstaging or primary non-surgical management in this setting.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_fe7828d3f3ed",
    "question": "In a premenopausal woman with ER-positive, HER2-negative metastatic breast cancer who has developed disease progression after first-line endocrine therapy, is it necessary to continue ovarian suppression if switching to subsequent lines of systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Metastatic (M1) invasive breast cancer",
            "Stage IV (M1) or Recurrent disease",
            "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
            "Stage IV (M1) or Recurrent",
            "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
            "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
            "Recurrent unresectable (local or regional) or stage IV (M1) disease",
            "Bone disease present",
            "Add denosumab zoledronic acid, or pamidronate",
            "ER- and/or PR-positive; HER2-negative",
            "BINV-22",
            "No visceral crisis and Prior endocrine therapy within 1 y",
            "Premenopausal",
            "Ovarian ablation or suppression + systemic therapy",
            "Continue endocrine therapy until progression or unacceptable toxicity",
            "Progression",
            "Progression or unacceptable toxicity on first-line endocrine therapy",
            "Systemic therapy",
            "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
            "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
          ]
        }
      }
    ],
    "answer": "Yes; ovarian ablation or suppression must be maintained in premenopausal women with ER-positive, HER2-negative metastatic breast cancer throughout all lines of systemic therapy, as ongoing ovarian estrogen production would otherwise diminish the efficacy of endocrine-based and most systemic treatments.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_a7a3b7967a5f",
    "question": "For a patient with stage I non-small cell lung cancer who underwent surgical resection but has positive surgical margins (R1, R2), is re-excision required as the only preferred option, or can radiotherapy serve as an acceptable alternative definitive treatment in this setting?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Re-excision is the preferred approach for stage I NSCLC patients with positive surgical margins, but definitive radiotherapy is an acceptable alternative option when resection is not feasible or contraindicated. Both strategies are recognized as appropriate for achieving local disease control in this context.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_74ce94faf920",
    "question": "For a patient with non-small cell lung cancer presenting with a separate pulmonary nodule located in the same lobe as the primary tumor (classified as T3, N0–1), is surgery following planned preoperative systemic therapy contingent upon having negative mediastinal nodal status (N0–1), or would the presence of N2 disease preclude immediate surgical intervention in favor of chemoradiation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
            "Surgery after preoperative systemic therapy, if planned",
            "N2",
            "Margins positive",
            "R2",
            "Concurrent chemoradiation",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "Surgery following planned preoperative systemic therapy is appropriate when mediastinal lymph node status is N0–1; the presence of N2 involvement shifts the preferred treatment to concurrent chemoradiation rather than immediate surgery, due to higher risk of systemic disease and local recurrence.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_6010c50cdd2e",
    "question": "In a patient with multiple primary lung cancers staged as N0–1, where the dominant pulmonary nodule demonstrates documented growth and definitive local therapy is not feasible, if mediastinal lymph node recurrence arises without prior thoracic radiotherapy, can concurrent chemoradiation be appropriately considered, or does the initial multifocality or prior ineligibility for local therapy preclude this approach?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Multiple lung cancers (suspected or confirmed) (N0–1)",
            "Multidisciplinary evaluation",
            "Dominant nodule with evidence of growth",
            "Definitive local therapy not possible",
            "Palliative chemotherapy ± local palliative therapy or Observe",
            "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Concurrent chemoradiation remains an appropriate option for mediastinal lymph node recurrence in the absence of prior thoracic radiotherapy, regardless of initial multifocality or inability to pursue definitive local therapy for the primary disease. The recurrence location and radiotherapy history are the key determinants; initial unresectability or tumor multiplicity does not preclude concurrent chemoradiation for nodal recurrence.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_deb1d810c95b",
    "question": "For a patient with non-small cell lung cancer staged as T1aN0M0 who is operable, if preoperative pulmonary function testing (PFT) reveals severe impairment, is primary surgical resection with mediastinal lymph node dissection still the preferred initial treatment compared to non-surgical options?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Nodes negative",
            "Treatment (NSCL-9)",
            "T1, N0",
            "Operable",
            "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
            "Adjuvant Treatment (NSCL-4)",
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "No. In the setting of severe preoperative pulmonary dysfunction, primary surgical resection—even in operable T1aN0M0 non-small cell lung cancer—may not be feasible or safe. Non-surgical modalities such as stereotactic body radiotherapy should be prioritized due to increased perioperative risk.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_d787e5030431",
    "question": "For a patient newly diagnosed with stage IVA (M1b) non-small cell lung cancer (NSCLC) of adenocarcinoma subtype, is broad molecular profiling including EGFR, ALK, ROS1, BRAF, KRAS, NTRK, METex14, RET, and HER2 testing appropriate if the individual has a known history of large cell histology and insufficient tissue for initial molecular analysis?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Yes, broad molecular profiling is still appropriate for advanced or metastatic non-squamous NSCLC such as adenocarcinoma or large cell histology, even if the initial tissue sample is insufficient. In this scenario, re-biopsy or plasma-based testing should be considered to ensure adequate molecular testing and guide targeted therapy decisions.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_4987fa4e0839",
    "question": "For a patient with Stage IA (T1abc, N0) non-small cell lung cancer who has undergone a resection with positive surgical margins (R1 or R2), is radiotherapy an equally preferred alternative to re-resection as primary management for margin positivity, or is it considered a secondary choice?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Radiotherapy is considered a secondary (category 2B) option for positive surgical margins (R1 or R2) after resection in Stage IA (T1abc, N0) non-small cell lung cancer; re-resection is the preferred management when feasible.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_86bbf06ce872",
    "question": "In a patient with non-metastatic, invasive breast cancer (clinical stage cT2, ER-positive and HER2-positive, with at least one ipsilateral lymph node metastasis >2 mm detected post-surgery), is adjuvant chemotherapy with trastuzumab plus pertuzumab and endocrine therapy preferred over adjuvant chemotherapy with trastuzumab and endocrine therapy alone, and what clinical situation would justify selection of one regimen over the other?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
            "ER-positive and/or PR-positive",
            "HER2-positive",
            "BINV-5",
            "Ductal/NST • Lobular • Mixed • Micropapillary",
            "pN+ (≥1 ipsilateral metastases >2 mm)",
            "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred) and endocrine therapy",
            "Follow-Up (BINV-17)"
          ]
        }
      }
    ],
    "answer": "Adjuvant chemotherapy with trastuzumab plus pertuzumab and endocrine therapy is preferred for patients with HER2-positive, node-positive early breast cancer, due to superior efficacy shown in high-risk groups. Chemotherapy with trastuzumab without pertuzumab may be considered only if pertuzumab is contraindicated or not tolerated. Node positivity and HER2 overexpression strongly support dual HER2 blockade unless there are adverse factors.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f208b9d51df3",
    "question": "In a patient with NSCLC classified as Stage II (T1abc–2ab, N1; T2b, N0) who presents with limited, surgically resectable brain metastasis (M1b), should the initial management prioritize local thoracic disease control or immediate treatment of the brain metastasis, and what is the rationale for this prioritization?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "PS 0–2",
            "Limited progression confirmed",
            "Other site",
            "Treatment of Thoracic Disease (NSCL-16)"
          ]
        }
      }
    ],
    "answer": "For NSCLC patients with Stage II thoracic disease and limited, resectable brain metastasis, immediate treatment of the brain metastasis (such as surgery or stereotactic radiosurgery) is prioritized to prevent neurological deterioration, followed by local thoracic management. Prompt control of symptomatic or potentially life-threatening CNS lesions is essential before addressing the primary thoracic tumor.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_0d2ea26bc99b",
    "question": "For a patient with NSCLC who is found to have supraclavicular lymph node involvement (N3) and no evidence of extrathoracic metastatic disease on FDG-PET/CT, is definitive concurrent chemoradiation still an appropriate treatment approach, or does the N3 status necessitate immediate systemic therapy for distant disease?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "In NSCLC patients with N3 mediastinal or supraclavicular lymph node involvement but no extrathoracic metastases, definitive concurrent chemoradiation remains an appropriate curative-intent option. Systemic therapy for distant disease is reserved for cases with confirmed extrathoracic metastases, not solely N3 nodal status.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_0e53f4c7f578",
    "question": "For a patient with stage IIIA non-small cell lung cancer (T1–2, N2; T3, N1) who has undergone complete (R0) surgical resection followed by sequential chemotherapy, is routine FDG-PET/CT or brain MRI with contrast indicated during surveillance if there is no clinical or radiographic evidence of disease recurrence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
            "Sequential chemotherapy and consider RT",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, in the absence of clinical or radiographic evidence of recurrence, routine use of FDG-PET/CT or brain MRI with contrast is not indicated for post-treatment surveillance in stage IIIA non-small cell lung cancer; follow-up should focus on history, physical examination, and chest CT at recommended intervals.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ed4014a09f1b",
    "question": "In a patient with pathologically confirmed N3 non-small cell lung cancer (NSCLC) presenting with stage IIIC disease (T3, N3), if separate pulmonary nodules are also detected, does this finding extend the indication for management from locoregional to distant metastatic disease protocols?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, the presence of separate pulmonary nodules in a patient with stage IIIC (T3, N3) NSCLC reclassifies the disease to either stage IIIA, IIB, or IV, depending on the location and characteristics of the nodules. This shifts management from locoregional to protocols appropriate for limited or distant metastatic disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_4446dd5fdd7f",
    "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete surgical resection but has positive margins (R1 or R2), is adjuvant external-beam radiotherapy routinely indicated regardless of prior chemotherapy administration, or is its use limited to specific clinical scenarios?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIA (T2b, N0); Margins positive (R1, R2)",
            "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Severe hemoptysis",
            "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Adjuvant external-beam radiotherapy after surgery with positive margins (R1 or R2) in stage IIA non-small cell lung cancer is not routinely indicated for all patients; its use is typically considered in cases with residual microscopic or gross disease, and the decision may depend on prior chemotherapy and patient-specific risk factors.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_7d1a1665c2e1",
    "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete surgical resection with negative margins (R0), is routine surveillance with FDG-PET/CT and brain MRI with contrast recommended during follow-up if there is no clinical or radiographic evidence of disease recurrence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIA (T2b, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, in the absence of clinical or radiographic suspicion of recurrence, routine surveillance with FDG-PET/CT and brain MRI with contrast is not recommended after R0 resection for stage IIA non-small cell lung cancer. Standard follow-up entails history, physical examination, and chest CT at specified intervals.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1ba9fdc435b0",
    "question": "In a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer, hormone receptor-negative (ER-negative, PR-negative), HER2-negative, with a primary tumor size of 0.9 cm (pT1), and axillary node status pN0, is adjuvant chemotherapy still considered appropriate if the patient has a significant cardiac comorbidity that increases the risk of anthracycline toxicity?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
            "ER-negative and PR-negative",
            "HER2-negative",
            "BINV-10",
            "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
            "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
            "Tumor 0.6–1.0 cm",
            "Consider adjuvant chemotherapy",
            "Follow-Up (BINV-17)"
          ]
        }
      }
    ],
    "answer": "Adjuvant chemotherapy may be considered for hormone receptor-negative, HER2-negative, node-negative breast cancer with a tumor size of 0.9 cm; however, significant cardiac comorbidity contraindicates standard anthracycline-based regimens. Alternative non-anthracycline chemotherapy could be considered, but the risk–benefit ratio must be carefully assessed given increased toxicity risk.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b948bc485582",
    "question": "For a patient with resected stage IIIA non-small cell lung cancer (T1–2, N2) who achieved R0 (negative) surgical margins and completed recommended adjuvant systemic chemotherapy, is routine use of FDG-PET/CT or brain MRI with contrast indicated during scheduled surveillance follow-up if there is no clinical or radiographic evidence of recurrence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Routine use of FDG-PET/CT or brain MRI with contrast is not indicated during surveillance follow-up in this scenario without evidence of recurrence; standard follow-up should include history and physical examination and chest CT at specified intervals, reserving advanced imaging for suspicion of relapse or new symptoms.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_e26564e49458",
    "question": "In a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer, clinical stage cT2N0, who is HER2-negative and triple-negative, is preoperative systemic therapy indicated based on standard criteria, or should primary surgery be prioritized in this setting?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS possible",
            "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
            "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
            "cN+ and ypN0: Strongly consider RT to the chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
          ]
        }
      }
    ],
    "answer": "For a patient with cT2N0 breast cancer who is HER2-negative and triple-negative, preoperative systemic therapy is indicated according to current selection criteria. Primary surgery is not prioritized over neoadjuvant therapy in this scenario, as systemic treatment before surgery can improve pathologic response rates and guide further management.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c383b1700a2c",
    "question": "In a patient with newly diagnosed stage IIIC (T4, N3) non-small cell lung cancer (NSCLC) with confirmed mediastinal N3 disease, if distant metastases are found on FDG-PET/CT, should systemic therapy be prioritized over local curative treatments such as surgery or definitive chemoradiotherapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
            "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "Yes, the detection of distant metastases in stage IIIC (T4, N3) NSCLC indicates metastatic disease, where curative local treatments are no longer appropriate. Systemic therapy becomes the primary treatment approach, as the goal shifts from local control to managing disseminated disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_47b7a33ef53d",
    "question": "For a patient with pathologically confirmed stage IIIC (T3, N3) non–small cell lung cancer who has not previously undergone a brain MRI or FDG-PET/CT, is it appropriate to proceed directly to metastatic disease treatment without first completing these imaging assessments?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "PS 3–4",
            "Systemic Therapy for Metastatic Disease (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, it is not appropriate. Brain MRI with contrast and FDG-PET/CT are essential for accurate staging and detection of occult metastases. Skipping these imaging studies may lead to inappropriate treatment selection and missed metastatic sites, thus violating standard diagnostic and therapeutic sequencing.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_6f60abdc5bae",
    "question": "In a patient newly diagnosed with stage IIIA non-small cell lung cancer (T3, N1) and symptomatic superior vena cava (SVC) obstruction who has not received prior chemoradiation, is concurrent chemoradiation with or without SVC stenting preferred over external-beam radiotherapy alone for immediate management?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Yes, concurrent chemoradiation with or without SVC stenting is the preferred immediate management for symptomatic SVC obstruction in untreated stage IIIA non-small cell lung cancer, as it addresses both tumor control and symptom relief. External-beam radiotherapy alone is an alternative if chemoradiation is not feasible, but combined modality therapy offers superior disease control.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_39df7b0bb22f",
    "question": "In a patient with stage IIIB non-small cell lung cancer characterized by T1–2 primary tumor and confirmed N3 nodal involvement, if the pulmonary function tests reveal severely impaired lung function, is surgical resection still considered an appropriate initial treatment option compared to non-surgical local therapies such as external-beam radiation or SABR?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "N3 nodes positive, M0",
            "Stage IIIB or Stage IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Surgical resection is generally contraindicated in patients with stage IIIB NSCLC and severely impaired pulmonary function. In such cases, non-surgical local therapies like external-beam radiation therapy or stereotactic ablative radiotherapy (SABR) are preferred due to unacceptable operative risk and likely poor postoperative outcomes.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_208b4f5c41a9",
    "question": "In a patient with stage IVA NSCLC presenting with malignant pleural effusion and confirmed BRAF V600E mutation, does the recommendation to perform broad molecular profiling and PD-L1 testing implicitly require that the histologic subtype is non-small cell lung cancer (NSCLC) of adenocarcinoma, large cell, or not otherwise specified (NOS), rather than squamous cell carcinoma?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1a: pleural or pericardial effusion",
            "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
            "Positive",
            "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "BRAF V600E mutation positive"
          ]
        }
      }
    ],
    "answer": "Yes, conducting broad molecular profiling and PD-L1 testing is primarily indicated for advanced-stage NSCLC with adenocarcinoma, large cell, or NOS histology, rather than squamous cell carcinoma, due to the higher prevalence of actionable molecular alterations in these subtypes.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_a2c1e016474e",
    "question": "In a patient with stage IIIA (T4, N1) non-small cell lung cancer that is deemed resectable and shows invasion into the mediastinum, if both concurrent chemoradiation and primary surgical resection are technically feasible, which treatment should be prioritized as initial management and why?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Stage IIIA (T4, N0–1)",
            "Treatment (NSCL-7)",
            "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
            "Systemic therapy or Concurrent chemoradiation",
            "Surgical reevaluation including chest CT ± PET/CT",
            "Surgery",
            "Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "For resectable stage IIIA (T4, N1) non-small cell lung cancer with mediastinal invasion, initial systemic therapy or concurrent chemoradiation is generally prioritized over immediate surgical resection. This approach increases the likelihood of margin-negative (R0) resection, addresses micrometastatic disease, and allows for surgical reevaluation based on treatment response. Direct surgery is typically reserved for select cases without bulky disease or major invasion precluding complete resection.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_448da40da5dd",
    "question": "For a patient with completely resected stage III NSCLC (T1–2, N2 or T3, N1 or T3, N2), with negative surgical margins and no evidence of residual or metastatic disease after adjuvant systemic therapy, is routine surveillance with brain MRI indicated in the absence of neurological symptoms?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Bone metastases",
            "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, routine surveillance with brain MRI is not indicated in asymptomatic patients with completely resected stage III NSCLC and no evidence of residual or metastatic disease. Brain MRI should be reserved for patients with neurological symptoms or suspected recurrence, as routine use is not supported in the absence of clinical concerns.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f626b209ec76",
    "question": "In patients with peripheral stage IA (T1abc, N0) non-small cell lung cancer undergoing resection, if preoperative pulmonary function tests (PFTs) have not been performed and the patient has a history of chronic obstructive pulmonary disease (COPD), can surgery proceed directly without PFT assessment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treatment",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
            "Surgery after preoperative systemic therapy, if planned",
            "N0–1",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "No, surgery should not proceed without preoperative pulmonary function tests in patients with stage IA NSCLC and a history of COPD. Assessment of lung function is essential to evaluate surgical risk and optimize perioperative management, regardless of tumor stage.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c12fc1deaa1e",
    "question": "In a patient with resected stage IIA (T2b, N0) non-small cell lung cancer who has undergone R0 surgery and is currently disease-free on imaging, is routine FDG-PET/CT or brain MRI surveillance recommended during follow-up, or should imaging be limited to scheduled chest CT scans?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIA (T2b, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Routine FDG-PET/CT and brain MRI are not recommended for surveillance in resected stage IIA (T2b, N0) non-small cell lung cancer patients without clinical or radiographic evidence of disease. Follow-up imaging should be limited to scheduled chest CT scans, with additional modalities reserved for suspected recurrence based on symptoms or findings.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3054f4abe65b",
    "question": "In patients with stage IIIA non-small cell lung cancer (T1–2, N2), if a contrast-enhanced brain MRI has not been previously performed, is omitting this imaging step acceptable prior to perioperative therapy initiation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Distant metastases",
            "Limited metastases",
            "Stage IV, M1b (NSCL-15)"
          ]
        }
      }
    ],
    "answer": "No, omission of a contrast-enhanced brain MRI prior to perioperative therapy in stage IIIA (T1–2, N2) non-small cell lung cancer is not acceptable, as occult brain metastases must be excluded to inform accurate staging and appropriate treatment planning.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_3c7003c1dfe1",
    "question": "In patients with multiple non-small cell lung cancers (N0–1 stage) where the dominant nodule shows evidence of growth but definitive local therapy is not feasible, does the choice of palliative chemotherapy ± local palliative therapy necessarily exclude the option of close observation?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Multiple lung cancers (suspected or confirmed) (N0–1)",
            "Multidisciplinary evaluation",
            "Dominant nodule with evidence of growth",
            "Definitive local therapy not possible",
            "Palliative chemotherapy ± local palliative therapy or Observe",
            "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, in patients with unresectable multiple lung cancers and a growing dominant nodule, palliative chemotherapy with or without local therapy does not strictly exclude close observation; both strategies remain options depending on symptom burden and overall patient status.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_629e39c8a8f5",
    "question": "In a patient with stage IIIA non-small cell lung cancer (T1–2, N2; T3, N1) who has undergone complete surgical resection with negative margins (R0), is brain MRI with contrast recommended as a routine part of initial surveillance if no neurological symptoms are present?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
            "Sequential chemotherapy and consider RT",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, routine brain MRI with contrast is not recommended for initial surveillance in stage IIIA non-small cell lung cancer after complete resection with negative margins, unless neurological symptoms or other clinical indications are present. Surveillance relies on history, physical examination, and chest CT.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c5100b000b9f",
    "question": "For a patient with stage IIB non–small cell lung cancer (T3, N0) who underwent complete surgical resection with negative margins and subsequently received adjuvant chemotherapy, is routine FDG-PET/CT indicated during scheduled surveillance imaging in the absence of any clinical or radiographic suspicion of recurrence?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Routine FDG-PET/CT is not indicated during surveillance for a stage IIB non–small cell lung cancer patient after complete resection and adjuvant chemotherapy if there is no evidence of clinical or radiographic recurrence; surveillance should consist of history, physical examination, and chest CT at defined intervals.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_f189a6d96c2a",
    "question": "In a patient with newly diagnosed non-small cell lung cancer presenting with T2 primary tumor and biopsy-confirmed N3 supraclavicular lymph node involvement but no detected distant metastases, is initial surgical resection an appropriate first-line treatment option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "N3 nodes positive, M0",
            "Stage IIIB or Stage IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, initial surgical resection is not appropriate; biopsy-confirmed N3 supraclavicular lymph node involvement in non-small cell lung cancer without distant metastases denotes stage IIIB/C disease, which is not considered operable. The standard management prioritizes systemic therapy or chemoradiation rather than upfront surgery.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2927bede55f3",
    "question": "For a patient with stage IB (T2a, N0) non-small cell lung cancer who has undergone complete surgical resection with negative margins, does the consideration of adjuvant systemic therapy inherently assume the presence of additional high-risk pathologic features, or can it be justified solely by the stage and margin status?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (T2a, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Locoregional recurrence",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "The consideration of adjuvant systemic therapy after complete resection with negative margins in stage IB (T2a, N0) non-small cell lung cancer generally presumes the existence of additional high-risk pathologic features; routine use based only on stage IB and negative margins is not standard without further high-risk factors such as lymphovascular invasion, poorly differentiated histology, or vascular invasion.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9741a4251228",
    "question": "In a patient with advanced or metastatic non-small cell lung cancer (NSCLC), histologically confirmed as adenocarcinoma and harboring an NTRK1 gene fusion detected before any systemic therapy, is it necessary to confirm EGFR mutation, ALK rearrangement, or PD-L1 status before initiating first-line NTRK inhibitor therapy such as larotrectinib or entrectinib?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "NTRK1/2/3 gene fusion positive",
            "NTRK1/2/3 gene fusion",
            "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
            "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
            "Progression",
            "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
            "Progression",
            "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
          ]
        }
      }
    ],
    "answer": "No, the identification of an NTRK1 gene fusion prior to first-line treatment is a sufficient molecular indication to initiate first-line NTRK inhibitor therapy, such as larotrectinib or entrectinib, regardless of EGFR mutation, ALK rearrangement, or PD-L1 status. Additional biomarker results are not required to proceed with these targeted agents.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_6d721f71ce6f",
    "question": "For a patient with stage II non-small cell lung cancer who completed definitive radiotherapy as primary treatment and now presents with completely resected oligometastatic disease, is the follow-up imaging schedule identical to a stage I–II patient who received only surgery and chemotherapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "No, the follow-up imaging schedule differs. Patients with stage II non-small cell lung cancer treated with definitive radiotherapy or those with oligometastatic disease treated definitively require more frequent imaging—specifically, chest CT every 3–6 months for 3 years—compared to surgery±chemotherapy alone, which is followed by chest CT every 6 months for 2–3 years.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1d09b9de3281",
    "question": "In patients with non-small cell lung cancer (NSCLC) who have biopsy-proven synchronous lesions suggestive of multiple primary lung cancers and also present with a separate pulmonary nodule in the same lobe (T3, N0–1), should the disease be managed as intrapulmonary metastasis or as synchronous primary tumors, and how does this distinction affect the appropriate therapeutic approach?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
            "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Disease outside of chest",
            "Systemic therapy for metastatic disease (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "When biopsy confirms synchronous lesions suggestive of multiple primary lung cancers, the disease should be managed as synchronous primary tumors, not intrapulmonary metastases. This distinction warrants individual staging and potentially curative treatment for each lesion, often favoring surgical resection or combined-modality therapy rather than systemic therapy typically used for metastatic disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_29165dedf6f2",
    "question": "For a patient with advanced or metastatic squamous cell carcinoma of the lung who is found to have an ERBB2 (HER2) mutation by broad molecular profiling, does the presence of this mutation automatically imply eligibility for targeted therapy regardless of PD-L1 expression status?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "ERBB2 (HER2) mutation positive"
          ]
        }
      }
    ],
    "answer": "No. Although the identification of an ERBB2 (HER2) mutation suggests potential eligibility for HER2-targeted therapy, current clinical practice typically prioritizes immunotherapy based on PD-L1 expression in squamous cell carcinoma. Targeted therapy eligibility remains investigational for ERBB2 mutations in this context and does not override standard PD-L1-driven treatment algorithms.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_efb6527c38ce",
    "question": "In a patient with a biopsy-proven synchronous lung lesion in a different lobe of the ipsilateral lung and no evidence of distant metastasis, does the presence of such a lesion automatically upstage the disease to stage IV non-small cell lung cancer (NSCLC)?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
            "Treatment",
            "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
            "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Disease outside of chest",
            "Systemic therapy for metastatic disease (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No; a synchronous nodule in a different lobe of the ipsilateral lung corresponds to T4 disease (stage IIIA or IIIB, depending on nodal status) rather than stage IV. Stage IV is reserved for distant metastases, including disease outside of the chest.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ece872cd6aea",
    "question": "In a patient with localized, non-inflammatory, non-metastatic (M0) breast cancer, clinical stage cT2, HR-negative, and HER2-positive disease who, after preoperative systemic therapy, is found to have ypT2, ypN1 disease, is the use of adjuvant ado-trastuzumab emtansine for 14 cycles appropriate even if axillary lymph node involvement (ypN≥1) persists after therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Considering preoperative systemic therapy",
            "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
            "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
            "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
            "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
            "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
            "Preoperative systemic therapy based on HR and HER2 status",
            "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
            "BCS possible",
            "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
            "Adjuvant systemic therapy (BINV-16), no RT",
            "HR-negative/ HER2-positive",
            "ypT1–4,N0 or ypN≥1",
            "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
          ]
        }
      }
    ],
    "answer": "Yes, in HR-negative, HER2-positive breast cancer patients with residual invasive disease in the breast or persistent axillary lymph node involvement (ypN≥1) after preoperative systemic therapy, adjuvant ado-trastuzumab emtansine for 14 cycles is indicated regardless of nodal status, provided M0 disease is present.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_4a2a55f97661",
    "question": "For a patient with stage I non-small cell lung cancer (NSCLC) who underwent primary surgical resection without adjuvant radiotherapy and is currently free of clinical or radiographic evidence of disease, is routine annual brain MRI surveillance recommended as part of standard follow-up?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results (NSCL-20)"
          ]
        }
      }
    ],
    "answer": "No, routine annual brain MRI surveillance is not recommended for a stage I NSCLC patient post-surgery without adjuvant radiotherapy and no evidence of recurrence; brain MRI is reserved for recurrence evaluation or if clinically indicated, not for routine surveillance in early-stage disease.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_a5ac12f1563e",
    "question": "In a premenopausal woman with invasive, HER2-negative, ER-positive and/or PR-positive ductal breast carcinoma, clinical stage T2N0M0, who is not considered for preoperative systemic therapy and undergoes breast-conserving surgery with negative axillary nodes, is adjuvant endocrine therapy reasonable if the primary tumor measures 0.4 cm (≤0.5 cm), or does its small size preclude the need for endocrine therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
            "Clinical Stage cT1–T4, 2cN0,M0",
            "Criteria for preoperative systemic therapy (BINV-M)",
            "Not considering preoperative systemic therapy",
            "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
            "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
            "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
            "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
            "ER-positive and/or PR-positive",
            "HER2-negative",
            "Premenopausal",
            "pT1-3 AND pN0",
            "Ductal/NST, Lobular, Mixed, Micropapillary",
            "Tumor ≤0.5 cm and pN0",
            "Consider adjuvant endocrine therapy (category 2B)",
            "Follow-Up (BINV-17)"
          ]
        }
      }
    ],
    "answer": "For a premenopausal woman with invasive, ER-positive and/or PR-positive, HER2-negative, node-negative breast cancer and a tumor size of ≤0.5 cm, adjuvant endocrine therapy may be considered according to category 2B evidence, indicating that the option remains reasonable even for tumors of this small size and is not categorically precluded.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_922227594f3e",
    "question": "In a patient with stage IIIA non-small cell lung cancer who achieved an R0 resection and completed sequential chemotherapy, if new small asymptomatic lung nodules are detected on surveillance imaging but there is no evidence of disseminated disease on chest CT and PET/CT, should observation be preferred over initiation of systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
            "Sequential chemotherapy and consider RT",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "Yes, in the absence of disseminated disease and if the nodules are asymptomatic and stable, observation is preferred over systemic therapy. Systemic therapy is reserved for cases with evidence of recurrence or disseminated disease, while observation is appropriate when curative treatment has been completed and no progression is detected.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_20408db15ffe",
    "question": "In a patient with completely resected Stage IIIA (T1–2, N2) non-small cell lung cancer who had positive surgical margins (R1), if chemoradiation is delivered sequentially rather than concurrently, does this choice imply any difference in required surveillance imaging frequency in the first three years after treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
            "R1; Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, for patients with Stage III non-small cell lung cancer treated with chemoradiation following positive margin resection, the surveillance protocol—chest CT with or without contrast every 3–6 months for the first 3 years—remains the same, regardless of whether chemoradiation was delivered sequentially or concurrently.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ec885b68f7c5",
    "question": "In a patient with advanced or metastatic squamous cell lung carcinoma who is confirmed to have a RET rearrangement prior to any systemic therapy, does this molecular finding justify the consideration of cabozantinib as a first-line therapy, or is it preferable to prioritize established RET inhibitors such as selpercatinib or pralsetinib if available?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "RET rearrangement positive",
            "RET rearrangement",
            "RET rearrangement discovered prior to first-line systemic therapy",
            "First-Line Therapy",
            "Useful in Certain Circumstances Cabozantinib",
            "Progression",
            "Subsequent Therapy",
            "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
          ]
        }
      }
    ],
    "answer": "For advanced or metastatic squamous cell lung carcinoma with confirmed RET rearrangement before systemic therapy, established RET inhibitors like selpercatinib or pralsetinib are the preferred first-line options if available, due to superior efficacy and safety profiles; cabozantinib is considered only when these agents are inaccessible.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_85b182f30ff8",
    "question": "In a patient with advanced or metastatic squamous cell carcinoma of the lung who has undergone broad molecular profiling and is negative for EGFR, ALK, KRAS, ROS1, BRAF, NTRK, METex14, RET, and ERBB2 (HER2) mutations and has a PD-L1 expression level less than 1%, is it justified to use immune checkpoint inhibitor monotherapy as initial systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Disseminated metastases",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above"
          ]
        }
      }
    ],
    "answer": "No, for advanced squamous cell lung carcinoma lacking actionable mutations and with PD-L1 expression below 1%, immune checkpoint inhibitor monotherapy is not indicated as initial systemic therapy; platinum-based chemotherapy, with or without immunotherapy in combination regimens, is the recommended first-line approach according to standard guidelines.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c73121b0c84f",
    "question": "For a patient with completely resected Stage IIB non-small cell lung cancer (T3N0, R0 margins) who remains disease-free after adjuvant chemotherapy, is routine use of FDG-PET/CT or brain MRI indicated during standard surveillance imaging in the first two years post-treatment?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
            "Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Endobronchial obstruction",
            "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Routine use of FDG-PET/CT or brain MRI is not indicated for surveillance in disease-free patients with Stage IIB non-small cell lung cancer post-complete resection and adjuvant therapy; surveillance should be performed with H&P and chest CT, reserving FDG-PET/CT or brain MRI only for suspected recurrence or new symptoms.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_c3e31d4dd50e",
    "question": "For a patient with stage IA (T1aN0) non-small cell lung cancer who has positive surgical margins (R1), is re-operation preferred over radiotherapy for margin management even if the patient has moderate chronic obstructive pulmonary disease and borderline pulmonary function?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (T1abc, N0); Margins positive (R1, R2)",
            "Resection (preferred) or RT (category 2B)",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Resectable recurrence",
            "Resection (preferred); External-beam RT or SABR",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Re-operation is generally preferred for positive margins in stage IA NSCLC; however, in patients with moderate COPD and borderline pulmonary function, the risks of surgery may outweigh benefits. In such cases, radiotherapy becomes an appropriate alternative for margin management despite being a category 2B option.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_330da861c40a",
    "question": "For a patient with stage I non–small cell lung cancer (T1, N0) who is deemed medically inoperable due to high surgical risk after evaluation by a thoracic surgeon, does the recommendation of definitive radiation therapy, preferably stereotactic ablative radiotherapy (SABR), implicitly exclude the use of surgical resection as a primary treatment option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Nodes negative",
            "Treatment (NSCL-9)",
            "T1, N0",
            "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
            "Definitive RT, preferably SABR",
            "Surveillance (NSCL-17)",
            "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
            "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
            "Distant metastases",
            "Therapy for Recurrence and Metastasis (NSCL-18)"
          ]
        }
      }
    ],
    "answer": "Yes, in patients with stage I (T1, N0) non–small cell lung cancer who are medically inoperable or have high surgical risk as determined by a thoracic surgeon, definitive radiation therapy—preferably SABR—is the standard approach, and surgical resection is not considered a viable primary treatment option in these circumstances.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_7a3041b58347",
    "question": "For a patient with stage II non-small cell lung cancer (T2b, N0), who also has severely reduced pulmonary function on pulmonary function tests (PFTs), is surgical resection still an appropriate first-line treatment option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Severe hemoptysis",
            "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, severely reduced pulmonary function on PFTs contraindicates surgical resection as first-line therapy in stage II NSCLC. In this context, alternative treatments such as definitive radiotherapy should be prioritized due to high perioperative risk with surgery.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_51a1a62c74a5",
    "question": "In a patient with newly diagnosed non-small cell lung cancer presenting with a T3N1 lesion (classified as stage IIIA), if pulmonary function tests (PFTs) reveal significant impairment and bronchoscopy shows central tumor involvement, is concurrent chemoradiation still an appropriate initial treatment option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Concurrent chemoradiation is generally not appropriate for patients with significant pulmonary dysfunction, especially when there is central tumor involvement, due to increased risk of severe toxicity. Adequate pulmonary function is a prerequisite for this modality; alternative treatment strategies should be considered in cases of compromised respiratory function.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_9a5ffb313e6f",
    "question": "In a patient with stage IIIA non-small cell lung cancer (T1–2, N2) who has previously undergone thoracic radiation therapy for another malignancy, is perioperative therapy with chemoradiation still an appropriate option, or should alternative systemic therapy be prioritized due to prior radiation exposure?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "Prior RT",
            "Systemic therapy (NSCL-19)",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "No evidence of disseminated disease",
            "Observation or Systemic therapy (category 2B)"
          ]
        }
      }
    ],
    "answer": "For stage IIIA (T1–2, N2) non-small cell lung cancer patients with prior thoracic radiation, concurrent chemoradiation carries increased risk of cumulative toxicity, particularly pulmonary and cardiac complications. Systemic therapy should be prioritized, as repeat radiation in previously treated fields is generally not recommended except in highly selected cases.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_1d90a65b3c20",
    "question": "In patients with non-small cell lung cancer (NSCLC) and confirmed stage IIIA disease due to positive mediastinal lymph nodes, does the presence of separate pulmonary nodule(s) in the same lobe alter the indication for perioperative therapy, or is systemic therapy for metastatic disease required instead?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Distant metastases",
            "Diffuse brain metastases",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "For stage IIIA NSCLC with positive mediastinal nodes, separate pulmonary nodules confined to the same lobe do not change the indication for perioperative therapy; management remains surgical or multimodal with curative intent. Systemic therapy for metastatic disease is considered only if nodules are in a different lobe or lung, which would upstage the disease to stage IV.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_2cdd0a0029d8",
    "question": "In a patient with non–small cell lung cancer presenting with a T3N1 tumor (AJCC Stage IIIA), pulmonary function tests reveal severely impaired lung function, but there is no extrathoracic metastatic disease or superior vena cava obstruction. Is perioperative therapy still a suitable consideration in this context?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Superior vena cava (SVC) obstruction",
            "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "No, perioperative therapy requires adequate cardiopulmonary reserve; severely impaired pulmonary function precludes surgery, making perioperative therapy unsuitable. Non-surgical, non-perioperative modalities, such as definitive chemoradiation or radiotherapy, should be considered instead in this situation.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_b0fcdd778253",
    "question": "In a patient with advanced non-squamous non-small cell lung cancer showing a KRAS G12C mutation, is it appropriate to prioritize targeted therapy against KRAS G12C over immunotherapy if programmed death ligand 1 (PD-L1) expression is high (≥50%)?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "KRAS G12C mutation positive"
          ]
        }
      }
    ],
    "answer": "For advanced NSCLC with a confirmed KRAS G12C mutation, current evidence supports prioritizing KRAS G12C-targeted therapy (such as sotorasib) after progression on first-line therapy. In cases of high PD-L1 expression (≥50%), first-line immunotherapy with or without chemotherapy remains the preferred initial option, as targeted KRAS therapy is typically reserved for subsequent lines.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_dc091b7ed936",
    "question": "In a patient with newly diagnosed stage IIIA (T1–2, N2) non-small cell lung cancer and no prior thoracic radiotherapy, if both surgery and concurrent chemoradiation are technically feasible, which treatment approach should be prioritized as the initial management strategy, and why?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
            "N1 or N2 disease",
            "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Metastatic disease",
            "Treatment for Metastasis limited sites or distant disease",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Concurrent chemoradiation should be prioritized as the initial management for stage IIIA (T1–2, N2) non-small cell lung cancer, given its established survival benefit and organ-preserving potential in this setting. Surgery is generally reserved for highly selected cases or as part of a multimodal approach post-induction therapy.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_ddeef184a722",
    "question": "In a patient with newly diagnosed metastatic squamous cell carcinoma of the lung who has negative results for EGFR, ALK, KRAS, ROS1, BRAF, NTRK, METex14 skipping, RET, and ERBB2 (HER2) mutations, as well as PD-L1 expression less than 1%, does this molecular profile preclude the use of first-line targeted therapy, and does it directly indicate the priority of systemic chemotherapy over targeted treatments?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Localized symptoms",
            "Palliative external-beam RT",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "PD-L1 <1% and negative for actionable molecular biomarkers above"
          ]
        }
      }
    ],
    "answer": "Yes, the absence of actionable molecular alterations and low PD-L1 expression preclude first-line targeted therapy in metastatic squamous cell lung cancer. In this context, systemic chemotherapy becomes the preferred initial treatment, as there are no molecular targets or high PD-L1 expression to justify targeted or immunotherapy as first-line options.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_4f73dc22a4d7",
    "question": "In a patient with advanced non-small cell lung cancer of adenocarcinoma subtype and confirmed bone metastases, if a high risk of pathological fracture is present, should orthopedic stabilization and palliative radiotherapy be implemented before initiating systemic therapy?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Distant metastases",
            "Bone metastases",
            "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
            "Systemic therapy (NSCL-19)",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
            "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
            "Testing Results",
            "EGFR exon 19 deletion or exon 21 L858R mutation positive"
          ]
        }
      }
    ],
    "answer": "Yes, in patients with bone metastases from advanced adenocarcinoma subtype NSCLC and high risk of fracture, orthopedic stabilization and palliative external-beam radiotherapy should be performed prior to starting systemic therapy to prevent skeletal-related events and ensure appropriate supportive management.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_338f0153e203",
    "question": "In a patient with stage IB (T2a, N0) non-small cell lung cancer (NSCLC) who has undergone complete surgical resection with negative margins (R0), is adjuvant systemic therapy considered standard for all such cases, or does the presence of certain risk factors influence this decision?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "Nodes negative",
            "Treatment (NSCL-9)",
            "T1, N0",
            "Operable",
            "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
            "Adjuvant Treatment (NSCL-4)",
            "Stage IB (T2a, N0); Margins negative (R0)",
            "Observe or Adjuvant Systemic Therapy (NSCL-E)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "Adjuvant systemic therapy is not standard for all stage IB (T2a, N0) NSCLC patients with R0 resection. The decision is influenced by high-risk features such as poor tumor differentiation, vascular invasion, wedge resection, minimal margins, or visceral pleural invasion; in their absence, observation is appropriate.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_34e15ecec405",
    "question": "In a patient with stage IIIA non-small cell lung cancer (T4 tumor invading the spine, N0–1), who also presents with mediastinal lymph node recurrence after initial surgery but has not previously received radiotherapy, is concurrent chemoradiation an appropriate treatment option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
            "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
            "Metastatic disease",
            "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
            "Locoregional recurrence or symptomatic local disease",
            "Mediastinal lymph node recurrence",
            "No prior RT",
            "Concurrent chemoradiation",
            "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
            "Evidence of disseminated disease",
            "Systemic therapy (NSCL-19)"
          ]
        }
      }
    ],
    "answer": "Yes, for stage IIIA NSCLC patients with mediastinal lymph node recurrence after surgery and no prior radiotherapy, concurrent chemoradiation is an established treatment strategy, as the absence of previous thoracic radiation allows for definitive local therapy targeting locoregional recurrence.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_520e17923d16",
    "question": "In a patient with non-small cell lung cancer staged as IIIB (T1–2, N3) confirmed by mediastinal lymph node biopsy, but with severely impaired pulmonary function on PFTs, is surgical resection still considered an appropriate initial treatment option?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
            "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
            "N3 nodes positive, M0",
            "Stage IIIB or Stage IIIC (NSCL-13)",
            "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
            "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
            "N3 negative",
            "Initial treatment for stage I–IIIA (NSCL-8)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Extrathoracic metastatic disease",
            "Treatment for Metastasis limited sites or distant disease"
          ]
        }
      }
    ],
    "answer": "No, surgical resection is not considered appropriate for stage IIIB (T1–2, N3) non-small cell lung cancer, especially when the patient presents with significantly impaired pulmonary function. For this stage and N3 involvement, non-surgical modalities such as chemoradiotherapy are standard; poor pulmonary reserve further contraindicates surgery due to high operative risk.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_79d8e4b4ea24",
    "question": "In a patient with stage IVA, metastatic (M1b) non-small cell lung cancer of squamous histology, who is found to have an NTRK1 gene fusion on molecular profiling prior to receiving any systemic therapy, is treatment with larotrectinib based on the assumption that broad molecular profiling—including NTRK fusion testing—has been successfully completed with adequate tissue sampling?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IVA, M1b",
            "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
            "Advanced or metastatic disease",
            "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
            "Squamous cell carcinoma",
            "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
            "Testing Results",
            "NTRK1/2/3 gene fusion positive",
            "NTRK1/2/3 gene fusion",
            "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
            "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
            "Progression",
            "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
            "Progression",
            "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
          ]
        }
      }
    ],
    "answer": "Yes, initiating larotrectinib in this scenario presumes that comprehensive molecular profiling has been performed using sufficient tumor tissue, confirming the presence of an actionable NTRK1 gene fusion as a driver alteration before starting first-line systemic therapy.",
    "type": "diagnostic_pathway"
  },
  {
    "id": "path_a05cfc5202d0",
    "question": "In a patient with stage IA peripheral non-small cell lung cancer (T1a-c, N0), if preoperative pulmonary function tests reveal severely impaired respiratory reserve, is surgical resection still considered the preferred primary treatment approach?",
    "tool_calls": [
      {
        "tool": "oncology.path_query",
        "params": {
          "nodes": [
            "Stage IA (peripheral T1abc, N0)",
            "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
            "Positive mediastinal nodes",
            "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
            "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
            "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
            "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
            "Treatment",
            "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
            "Surgery after preoperative systemic therapy, if planned",
            "N2",
            "Margins positive",
            "R1",
            "Chemoradiation (sequential or concurrent)",
            "Surveillance (NSCL-17)"
          ]
        }
      }
    ],
    "answer": "For stage IA peripheral NSCLC, surgical resection is generally the standard primary treatment; however, in the presence of severely impaired pulmonary function, surgery is contraindicated due to high perioperative risk. In such cases, non-surgical options such as stereotactic body radiotherapy (SBRT) are preferred.",
    "type": "diagnostic_pathway"
  }
]